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Abstract 
Purpose: The etiology and pathogenesis of uveitis associated with Juvenile Idiopathic Arthritis 
(JIA) are poorly understood.  The purpose of this rat-based research is to explore the potential of 
a shared collagen based self-antigen within the joint and eye in the rat as a factor involved in the 
etiopathogenesis of arthritis and associated uveitis. As young age and female sex are risk factors 
for uveitis in children with JIA, their influence on experimental autoimmune anterior uveitis in 
the rat was evaluated by ophthalmic evaluation with biomicroscopic, light microscopic ocular 
examinations, and pro-inflammatory vitreous cytokine profiles. 
Methods: Adult and juvenile male and female Lewis rats were inoculated intradermally with 
either: intact type I collagen derived from bovine skin, type II collagen, or derivatives of type I 
collagen including melanin associated antigen (MAA) or soluble MAA which was digested in 
Staphylococcal V8 protease, Streptococcus streptokinase C, or matrix metalloproteinase (MMP)-
1. Inoculations were repeated up to three times at intervals of 1 or 4 weeks. Biomicroscopic and 
indirect ophthalmic examinations were completed in live rats at baseline and biomicroscopic 
examinations were repeated three time per week throughout the study period by a masked 
Diplomate of the American College of Veterinary Ophthalmologists (ACVO). At the end of the 
observation period globes were enucleated and vitreous was aspirated. Histopathology slides of 
the globes were reviewed by a masked Diplomate ACVO. Rats treated with insoluble MAA had 
clinical uveitis scores, ocular histopathological scores, and cytokine analysis compared between 
age and sex groups and control animals. An array of 27 cytokines were quantified with a 
multiplex bead-based immunoassay on vitreous from rats treated with MMP-1 digested type I 
collagen derived from bovine skin, or type II collagen derived from bovine cartillage, and rats 
treated with insoluble melanin associated antigen. Immunohistochemical labels for CD43 and 
CD45RC were compared between solubilized MAA groups and control animals. 
 Results: None of the rats inoculated with any form of type I collagen derived from bovine skin, 
or type II collagen derived from bovine cartilage, developed uveitis that could be detected 
clinically or light microscopically. 28/44 rats inoculated with intact type II collagen developed 
arthritis. Vitreous cytokine levels did not differ between any treatment group and controls. All 
rats inoculated with insoluble MAA developed uveitis on biomicroscopic and light microscopic 
examination and no differences were identified between age and sex groups. Uveitis was present 
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in 3/12 Staphylococcus aureus V8 protease MAA inoculated rats and 2/12 streptokinase C 
solubilized MAA inoculated rats.  
Conclusions:  None of the digested or intact forms of type I collagen derived from bovine skin, 
or type II collagen derived from bovine cartilage, resulted in uveitis in the Lewis rat. While type 
II collagen induced arthritis, digestion of type II collagen renders it non-pathogenic. 
Streptococcus streptokinase C and Staphylococcus aureus V8 protease digested MAA induced 
uveitis in some rats when inoculations are repeated three times. Insoluble MAA induced uveitis 
in all rats and no difference in disease incidence, severity, or onset was observed between sexes 
or age groups in rats inoculated with MAA.   
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1. Literature Review 
 
1.1 Juvenile Idiopathic Arthritis 
JIA is a heterogeneous group of autoimmune arthritides of unknown etiology lasting longer than 
six weeks and having onset in children less than 16 years of age1. It is the most common form of 
arthritis in children in the western world2.  In most cases the disease remains active for years and 
persists into adulthood3,4. JIA is likely influenced by interacting genetic and environmental 
factors5-9. 
 
There are seven JIA categories1  
1. Systemic JIA: Arthritis in one or more joints with or preceded by fever of at  least two weeks 
duration that has been documented to be daily for at least three days and accompanied by one 
or more of the following: evanescent erythematous rash, generalized lymph node 
enlargement, hepatomegaly and/or splenomegaly, and serositis 
2. Oligoarticular: Arthritis affecting one to four joints during the first six months of disease. 
Includes a persistent form in which no more than four joints are involved during the course of 
the disease or an extended form in which more than four joints become involved after the 
first six months. 
3.  Rheumatoid factor-negative polyarthritis:  Arthritis affecting five or more joints during the 
first six months of disease with a negative test for rheumatoid factor.  
4. Rheumatoid factor-positive polyarthritis:   Arthritis affecting five or more joints during the 
first six months of disease with a positive test for rheumatoid factor as documented on at 
least two occasions at least three months apart. 
5. Psoriatic: Arthritis and psoriasis or arthritis and at least two of the following: Dactylitis, nail 
pitting or onycholysis, psoriasis in a first degree relative  
6. Enthesitis-related arthritis: Arthritis and enthesitis or arthritis and two or more of the 
following: 
●Sacroiliac joint tenderness 
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●Inflammatory spinal pain 
●Human leukocyte antigen (HLA)-B27 
●Positive family history of anterior uveitis with pain, a spondyloarthropathy, or inflammatory 
bowel disease 
●Anterior uveitis associated with pain, redness, or photophobia 
 
7. Undifferentiated arthritis: Arthritis that fulfills criteria in no category or in two or more of the 
above categories. 
 
1.2 JIA-uveitis 
Uveitis, which is inflammation in the uvea, is the most common debilitating extra-articular 
manifestation of JIA10.   Between 9.2% and 13.1% of children with JIA develop uveitis11-13.  JIA-
uveitis makes up between 15 and 67% of all pediatric uveitis presenting to tertiary referral 
centers 14-18. Uveitis associated with JIA is an important cause of vision loss and blindness in 
developing countries19-22. 
 
 
1.2.1 Clinical Presentation and Outcome 
 JIA-uveitis can be acute, subacute, chronic or recurrent and its location within the eye can be 
anterior, intermediate or pan-uveal. The most common form is a chronic anterior uveitis 
occurring in 68% of children with JIA-uveitis23. Acute anterior, recurrent anterior and panuveitis 
also occur with JIA albeit less frequently than chronic anterior uveitis, with their incidence 
occurring in 16.2,12, and 3.5% of cases respectively23. The chronic asymptomatic uveitis is 
typical of children with the oligoarticular subtype of JIA while the acute, symptomatic form is 
characteristic of the enthesitis-related subtype of JIA. The chronic anterior uveitis is most 
common in females, and children diagnosed at a young age. Males are more likely to have acute 
symptomatic uveitis23. The uveitis is more often bilateral (60.6%) but can be unilateral23. It is 
most commonly asymptomatic, insidious in onset, and many children are too young to 
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communicate or discern changes in visual acuity. This clinically silent nature of the disease may 
result in advanced pathology at the time of diagnosis23. Regular screening for uveitis in children 
with JIA is recommended to allow detection and prevent vision threatening complications.  
A significant improvement in uveitis control has been observed over the past decades24-25. In one 
study 30% of children had inactive uveitis in 2002, while 65% were inactive in 201324. Advances 
in treatments have been credited for these successes. If uncontrolled clinical signs of uveitis can 
extend into adulthood and results in significant morbidity26-29. Despite progress in early detection 
and treatment of JIA-uveitis, vision-threatening complications have been reported in up to 60% 
of patients in some studies 28.  These vision disabling complications include band keratopathy, 
maculopathy (macular edema, macular cysts, and epiretinal membranes), glaucomatous optic 
neuropathy, and cataracts 28,26. Uveitis can precede development of arthritis in 3-7% of 
children30.  Discordant patterns of disease between the eye and the joint have been observed in 
70% of patients suggesting differences in pathogenesis of recurrence and initiation of arthritis 
and uveitis31. 
 
 
1.2.2 Risk Factors  
Risk factors for development of JIA-uveitis have been established and include HLA 
alleles, female sex, young age of onset, a positive test for anti-nuclear antibodies (ANA), and 
oligoarticular JIA10,32-33.  
There is substantial evidence for a genetic component of JIA. However, the multiple categories 
of JIA, its heterogeneous nature, and wide inclusion criteria for diagnosis of JIA, complicate 
genetic studies.  JIA has not demonstrated Mendelian or monogenic patterns of inheritance and 
the genetic basis for JIA and JIA uveitis is likely very complex and considered modest9. Despite 
its complexity, multiple factors demonstrate the role of genetics. Concordance rates amongst 
monozygotic twins (25-40%) are higher than the overall population risk of 1 in 100034. 
Aggregation of clinical features between affected sibling pairs and twin pairs also supports the 
role of genetics35-36.  Genetic analysis has identified JIA susceptibility loci in both human 
leukocyte antigen and non-human leukocyte antigens.  Susceptibility for development of 
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oligoarticular JIA has the most defined HLA associations including DRB1:01, DRB1:08, 
DRB1:11, DRB1:13, DPB1:02 and DQB1:0437. HLA DRB1*04 and DRB1*07 may be 
protective against development of oligoarticular JIA38. Human leukocyte antigen alleles HLA-
DRB1:11 and HLA-DRB1:13 increase the risk of uveitis development in children with JIA39.   
Female sex is a risk factor for the development of uveitis in JIA patients. More females than 
males develop uveitis19, 23, 40 with up to 79.6% of children that develop uveitis being female13. In 
addition to differences in prevalence between sexes, the disease onset and manifestations are also 
different. The risk of developing uveitis in girls with JIA is highest in girls aged 1-2 years 
old, whereas uveitis risk is not considered age-dependent in boys who are typically older than 
girls at the time of both JIA and uveitis diagnosis23. Only 15% of females present with uveitis as 
the initial manifestation of their disease, compared to 44% of males41, 42.  Males are more likely 
to have acute symptomatic uveitis and a shorter interval between diagnosis of arthritis and 
uveitis. Males with uveitis are more likely to have enthesitis‐related arthritis or psoriatic JIA, 
compared to females who were more likely to have oligoarticular JIA23. 
Disease severity and complication rates are also reported to vary between sexes, with males 
developing more severe disease and having a higher complication rate10, 13,14,41,43. It has not been 
determined if the increased likelihood of uveitis in girls is related to intrinsic biological 
differences between sexes, or if it can be attributed to the predominance of females with 
oligoarticular arthritis and positive ANA titer23. Autoimmune diseases in general are more 
prevalent amongst females with women making up 78% of those affected44-46. Basic immune 
responses differ between males and females. Women primarily respond to infection, trauma, and 
vaccination with classical Th2 mechanisms and increased antibody production. Men develop a 
stronger Th1 response which results in increased severity of inflammation47-52. Estrogen 
interaction with the immune system is complex and it exerts both suppressive and pro-
inflammatory roles51-53.  
A positive ANA titer is also a known risk factor for uveitis development.  In a Canadian study 
76% of children with JIA-uveitis were ANA positive54. A positive ANA test present at the onset 
of uveitis is likely to portend arthritis if arthritis is not already present55-56. ANA positivity is not 
predictive of uveitis severity, relapses or outcomes57. The antigenic specificity of ANAs in 
children with JIA, and the role of ANA in the pathophysiology of JIA are unknown58. 
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Young age at onset of arthritis is a risk factor for uveitis development. Children with an age of 
onset of JIA <4 years are at increased likelihood for developing uveitis.  Several HLA 
associations have been correlated with onset age. HLA class II associations have demonstrated 
specific age windows of susceptibility to JIA subtypes59.  HLA alleles associated with uveitis 
risk, HLA–DR11 and HLA–DR13, are more often observed in patients with disease onset before 
the age of 7 years59.  An increase in the number of HLA risk alleles predisposes to earlier 
development of JIA59.  Uveitis activity has demonstrated biphasic disease activity with a quiet 
phase around the age of 9 years followed by increased severity during early teenage years42.  
The oligoarticular form of JIA is a risk factor for the development of uveitis. In a Canadian study 
of children with JIA-uveitis 55% had oligoarticular arthritis, 22% had rheumatoid factor negative 
polyarthritis, 11% had undifferentiated arthritis, 3% had systemic JIA, and 1% had enthesis-
related arthritis54. Oligoarthritis and rheumatoid factor negative polyarthritis subtypes are 
significantly associated with uveitis development54. Young onset age and ANA positivity are 
typical of oligoarthritis and therefore while oligoarthritis may be associated with uveitis 
development it may actually have a higher incidence related to factors other than ANA positivity 
such as sex, onset age, and JIA category54. 
 
 
1.2.3  Ocular Pathology 
Few ocular tissues from children with JIA-uveitis are available for histopathologic analysis. 
Iridectomy samples of children with JIA-uveitis undergoing trabeculectomy demonstrated a 
slight predominance of CD4+ cells rather than CD8+ cells, and plasma cells and histiocytes were 
the cell type present most consistently60. These samples were obtained from eyes with minimal 
inflammation and the histologic picture may have been influenced by their treatment60. An 
enucleated globe from a patient with end stage JIA-uveitis identified B cells and plasma cells as 
the most abundant inflammatory infiltrate. Rare CD4+ and few CD8+ cells were present. Similar 
to the iridectomy sample discussed above, this histopathology may also have been influenced by 
the patient’s intense immunosuppressive therapy including anti-tumor necrosis factor (TNF)-ɑ 
treatment61. 
6 
 
 
1.2.4 Pathophysiology 
The underlying pathophysiology linking uveitis and arthritis in JIA-uveitis is unknown. It is 
believed to be a multifactorial autoimmune disorder occurring due to a combination of genetic, 
environmental, and infectious influences 5, 6, 8, 35. It has been proposed that an immune response 
occurs targeting known intraocular antigens like S-arrestin, retinol-binding protein 3, and 
tyrosinase related proteins 62-65. T-helper cell (Th)1, Th17, regulatory T cells (Tregs), and pro-
inflammatory cytokines contribute to JIA-uveitis  pathophysiology, however their roles remain to 
be fully elucidated66-72. 
 
1.3 Autoimmunity  
 Autoimmune disease is a dysregulation of the innate and adaptive immune system that leads the 
body to attack its own tissues. It occurs due to a loss of immune self-tolerance73-74. 
The normal function of the immune response is to eliminate a pathogen, minimize damage from 
the pathogen and prevent reinfection with the same pathogen. For this to occur, multiple steps 
occur to ensure the appropriate immune response is generated and to avoid aberrant self-
targeting. The immune system operates through two interacting branches; the innate system 
which is the immediate defense, and the adaptive which is a delayed but antigen-specific 
response. The two branches of the immune system are bridged through antigen presenting cells75. 
These cells continually collect molecules from pathogens, as well as molecules from self, due to 
normal cellular apoptosis and necrosis. The antigen presenting cells combine the collected 
molecules with major histocompatibility complex (MHC) proteins and display them on their 
surface as an MHC-antigen complex75. The antigen presenting cells express their MHC-antigen 
complex locally and also travel to lymph nodes and present their MHC-antigen complexes to 
peripheral T-helper lymphocytes. If the T helper cell has already been exposed to ongoing 
inflammation, or an antigen-specific immune response, it will have an antibody or a T cell 
receptor on its surface that binds to the MHC-antigen complex75. A further safeguard must be 
met for the adaptive immune response to occur which is either simultaneous binding of 
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coactivation molecules on the antigen presenting cell, or the presence of co-activating cytokines 
in the local environment. The type of co-activating molecule determines the type of immune 
response75. 
Complement is a major component of innate immunity and also plays a role in antigen 
processing and presentation, T-cell proliferation and differentiation, B-cell activation,76-77 and 
systemic tolerance induced by the introduction of antigen into an immune-privileged site such as 
the anterior chamber of the eye78. 
Cytokines are a group of small secreted proteins that act as chemical signals between cells79. 
Their physiologic role in inflammation and pathologic role in systemic inflammatory states are 
being increasingly recognized79. They can be produced in a cascade, act synergistically, or 
antagonistically with other cytokines. For example, anti-inflammatory cytokines control the pro-
inflammatory cytokine response. T cells and macrophages are known to produce pro-
inflammatory cytokines to upregulate inflammation79. In the normal physiologic state, pro-
inflammatory cytokines are maintained in equilibrium with anti-inflammatory cytokines. 
Inflammation shifts this equilibrium, and without inflammation, an immune response does not 
occur. When inflammation is present various cytokines activate antigen presenting cells so that 
they express surface based co-activation factors. Finally, co-activation factors together with T 
helper-antigen presenting cell complex leads to activation of the immune response79.   
In addition to the requirement of T helper cell binding to the MHC-antigen in the presence of co-
activation factors and inflammation, a further safeguard is in place to prevent aberrant activation 
of the immune response; thymic or central tolerance induction 80. This process deletes T cells 
that are reactive to self but the process is not absolute and self-reactive T cells can be found 
peripherally. These cells do not typically lead to the activation of an immune response because of 
the peripheral requirement for activation cofactors and T helper cell binding to antigen 
presenting cells with antigen MHC complexes81. 
 Triggering of autoimmunity has been suggested to occur through molecular mimicry, bystander 
activation, and epitope spreading.   Molecular mimicry occurs when a molecule is similar enough 
to cross react with a self-antigen but different enough to break immune tolerance82.  This 
mechanism was initially invoked to explain persistent viral infection and suggested that the 
MHC and viruses encoded similar antigens which allows the host to regard the virus as self82-83. 
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Shared epitopes between host and virus were demonstrated in 4% of a panel of 600 antibodies 
and several antibodies reacted with antigens in more than one organ84. Molecular mimicry has 
been demonstrated in a rat model of experimental autoimmune uveitis between retinal S-antigen 
peptide PDSAg and class I HLA B27PD amino acids 125-13882, 85-88. Epitope spreading occurs 
in the face of inflammation and tissue destruction where previously unrecognized epitopes 
become targeted by the immune response, and is characterized by recurrent relapses with 
recruitment of newly reactive T cells89-90. Epitope spreading has been recognized in Equine 
Recurrent Uveitis and has been implicated in the remitting-relapsing character of the disease91. 
Bystander activation occurs when a pathogen stimulates cytokines which lead to activation of 
unrelated pre-primed autoreactive T cells92-93.  
 
 
1.4 Cytokines as mediators of pathology  
Cytokines are considered the major mediators of joint damage in chronic arthritis. Several 
studies have evaluated cytokine expression in serum or synovial fluid of children with JIA and 
have found variable cytokine profiles94-100.TNF‐α, interleukin (IL) ‐6 and IL ‐8 are elevated in 
some JIA subtypes relative to other types or controls. TNF‐α, IL ‐1β, IL ‐6 and IL ‐17 levels are 
elevated in JIA patients with active disease when compared to those with inactive disease. Serum 
profiles of children with JIA and uveal tract inflammation have demonstrated increased 
concentrations of pro-inflammatory TNF-α and IL-17 cytokines along with reduced IFN-γ and 
increased IL-10 levels when compared to children with JIA and no signs of uveal tract 
inflammation101. 
Aqueous humor cytokine levels in children with JIA-uveitis demonstrate significantly higher 
levels of IL -2, IL -6, IL -13, IL -18, IFN-γ, TNF-α, sICAM-1, RANTES and IP-10 compared to 
control children without JIA or uveitis102. IL-8 and IL-10 levels in aqueous humor were 
significantly increased over control levels in a group of children with uveitis of varying etiology 
including JIA. No differences were found between cytokine levels in aqueous humor samples of 
patients with different types of JIA102. Another study comparing cytokines between children with 
JIA-uveitis and other childhood uveitidies found children with JIA-associated uveitis and those 
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with idiopathic uveitis not associated with JIA had distinct profiles of intraocular soluble 
mediators. Aqueous humor levels of IFNλ1 were specifically decreased in patients with JIA-
associated uveitis compared to children with idiopathic uveitis103. 
 
Even aqueous humor samples collected from children with clinically inactive uveitis 
demonstrated concentrations of IL-8, TGFβ-1, TGFβ-2, TGFβ-3, serum amyloid A, and TNF-α 
that were significantly elevated compared to controls104. Despite having clinically inactive JIA-
uveitis and receiving intensive anti-inflammatory treatment, these cytokine levels suggest that 
clinically inactive disease remains immunologically active104. Subclinical cytokine activity could 
serve as an early warning system to predict disease flares and allow for early intervention and 
more clearly defined treatment endpoints104.  
Variation in aqueous cytokine profiles between children and adolescents and adults have been 
reported. Sijssens et al (2008) found children and adolescents had different aqueous levels of Il-
1, IL-2, IL-4, IL-6, IL-10, IL-12 p-70, IL-13, IL-18, IFN-γ, TNF-α, sICAM-1, soluble vascular 
cell adhesion molecule 1, and Eotaxin compared to adults105. IL6 was the only cytokine 
significantly higher in adults whereas the remainder of them were significantly lower in 
adolescents and children. IP-10, RANTES, and IL-8 levels did not differ between age groups105. 
Gene associations coding for cytokines or their receptor have been described in children with 
oligoarticular JIA/polyarticular RF-negative JIA106. Tumor necrosis factor alpha gene encodes 
for pro-inflammatory cytokine TNFα and studies have identified associations between 
polymorphisms in the TNFA gene and JIA107-112. A particular allele, TNF G-30A has been 
identified repeatedly and in a meta-analysis113. There have also been reports of varied responses 
to therapy dependent on TNFA genotypes114. Polymorphisims in the macrophage migration 
inhibitory factor gene has also been associated with JIA 115-118 and a specific MIF -173 C allele 
has been identified that is associated with relapse117. The gene ILRA encodes the interleukin 
receptor alpha and has demonstrated associations with JIA119. CCR5 is a chemokine that 
promotes joint inflammation and a 32 base pair deletion in its gene has demonstrated a protective 
role against JIA120-121. 
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Inhibition of specific cytokines in the course of JIA is credited for the improvement in outcomes 
observed in affected children over the recent decades. These medications include TNFα 
inhibitors and monoclonal antibodies targeting IL-2 or IL-6 receptors122.  
1.5 Animal Models 
Animal models provide a valuable avenue for exploration of triggers, risk factors, 
pathophysiology, and treatments for human disease. Animal models can clarify pathogenesis by 
limiting variables, allowing study during early phases and providing longitudinal analysis of 
disease manifestation.  
A suggested pathogenesis for JIA-uveitis involves cross reactivity with antigens between the eye 
and the joint.  Collagen breakdown in either the eye or the joint via either an endogenous 
protease or exogenous protease may result in exposure of a collagen-related autoantigen. 
Currently, there is no animal model for JIA-uveitis but there is an established model for 
autoimmune anterior uveitis and an established model for autoimmune arthritis. Both of these 
models generate an autoimmune response to collagen.  Further investigation is required to 
determine if there is a shared collagen-based antigen between the eyes and joint that could be 
involved in the pathogenesis of arthritis-uveitis. 
Experimental models of either autoimmune uveitis or autoimmune arthritis can be initiated 
through inoculation with heterologous and homologous collagens123-125. Collagens are a family 
of fibrous proteins produced by many different cell types present throughout the body in many 
tissues. Over 25 different types of collagen have been recognized.  All collagen molecules share 
a similar biochemical structure characterized by triple helical configuration, glycine in every 
third amino acid position, and an abundance of proline/hydroxyproline and 
lysine/hydroxylysine126 . Although collagens are highly conserved proteins, tissue-specific 
structural differences have been noted127-129. 
1.5.1 Collagen Induced Arthritis 
Collagen-induced arthritis (CIA) is a form of experimental autoimmune arthritis that can be 
induced in genetically susceptible rats or mice following injection of bovine intact type II 
collagen. It is the most commonly studied autoimmune model of rheumatoid arthritis130. 
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Susceptibility to CIA is linked to major histocompatibility complex II genes and the 
immunopathogenesis involves both a T-cell and B-cell specific response to type II 
collagen131.The arthritis develops in the tarsal and metatarsal joints  21-28 days after 
immunization130. Pathological features include synovial hyperplasia, mononuclear cell 
infiltration, and cartilage degradation130.  The arthritis course and outcome vary depending on the 
age of animal inoculated132.  Estrogen has been shown to protect against CIA in DBA/1LacJ 
mice and Lewis rats, and male mice are more susceptible to CIA than female133-135. Uveitis has 
been reported in 10% of female Sprague-Dawley rats inoculated with type II collagen136.  Half of 
the affected rats had developed a concurrent arthritis while the other half had not136. Uveitis has 
also been documented in 1/15 rats receiving spleen cells from rats inoculated with type II 
collagen137.  Further investigations of uveitis in rats inoculated with type II collagen are 
warranted to improve our understanding of the link between the eye and joint in children with 
JIA-uveitis. 
 
1.5.2 Animal Models of Uveitis 
Posterior Uveitis Models 
Experimental autoimmune uveitis (EAU) induces a predominantly posterior uveitis with 
destruction of the retina. EAU is induced by inoculation with soluble retinal proteins, either 
interphotoreceptor binding protein138, S-antigen139, rhodopsin140, or transducin141. The 
predominantly posterior nature of EAU does not reflect the clinical characteristics of 
autoimmune anterior uveitis in people or juvenile arthritis/uveitis.    
 
Experimental Autoimmune Anterior Uveitis 
 Experimental autoimmune anterior uveitis (EAAU) is an animal model for human anterior 
uveitis. EAAU manifests as a severe bilateral predominantly anterior uveitis in nearly all rats 
approximately 11-15.5 days post inoculation124,142-144. Light microscopic examination of affected 
rats reveal a marked lymphocytic iritis and cyclitis 123, 124,142-146. CD4+ T cells predominate 
throughout the course of EAAU and a small number of CD8 T cells and macrophages have been 
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observed143. Antigen specific CD4+ T cells can adoptively transfer disease into naive syngeneic 
recipients123,143-144 whereas serum cannot143-144.  
 
The antigen in melanin associated antigen (MAA) has been identified as a 22 kDa fragment 
of  the α-2 chain of type 1 collagen found in the anterior uvea124.This experimental autoimmune 
uveitis model has been demonstrated using both heterologous (bovine) and homologous uveal 
type I collagen in the Lewis rat. Type I collagen is the most abundant collagen in the body and a 
key structural component of bones, tendons and ligaments147. Almost 50 different molecules that 
interact with type I collagen have been recognized147. Binding sites on type I collagen include 
sequences for integrins148-153 ,IL-2154,  Staphylococcus aureus cell surface molecules155, 
Staphylococcus aureus matrix binding proteins156, MMP-1157 and many others147. 
Immunohistochemistry of naive rats has demonstrated the presence of endogenous MAA in the 
normal iris and ciliary body124. 
 
To isolate the antigenic 22 kDa fragment of uveal type I collagen, MAA is digested by V8 
protease, a proteolytic enzyme secreted by Staphylococcus aureus. It is possible that other 
endogenous and exogenous proteases could play a role in collagen degradation in either the eye 
or the joint resulting in exposure of an antigenic peptide. For example, MAA digestion with 
MMP-1 results in a fragment of type 1 collagen between 20 and 25 kDa124, but the antigenicity 
of this fragment has not been evaluated. This suggests that MMP-1 may also play a role in the 
pathogenesis of JIA by acting endogenously to expose a shared pathogenic peptide between the 
joint and the eye.  
 
The digested MAA, referred to as “soluble MAA”, has demonstrated antigenicity only when 
administered in conjunction with complete Freund's adjuvant142, 144.  In its intact form prior to 
digestion it is also antigenic, even without the use of adjuvant. In the intact form, the MAA 
backbone has been speculated to act as an adjuvant142, 144.  
Without the use of adjuvant, soluble MAA has not induced uveitis. Complete Freund's adjuvant 
alone induces uveitis and arthritis136, 158  confounding results when it is used in conjunction with 
soluble MAA.  When CFA is injected at a dose of 0.25mg-1mg, more than 90% of Sprague 
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Dawley and Lewis rats develop histologic evidence of uveitis, while only 20-28% demonstrate 
uveitis on biomicroscopic examination136.  Complete Freund’s adjuvant contains inactive 
mycobacteria known to stimulate cell-mediated immunity, tumor necrosis factor dysregulation, 
and uveitis136, 137,158-159. Incomplete Freund’s adjuvant provides a water-oil emulsion to facilitate 
inoculation administration without immune stimulation. 
The majority of MAA studies have been completed in 6-8 week old male rats 123-124,142-144. 
EAAU has not been evaluated in adult rats, and 5-6 week old female rats have been evaluated in 
only one study144. No comparisons between adult and juvenile, nor male and female rats have 
been reported. It is unknown why differences in uveitis manifestation occur between male and 
female children with uveitis.  In a model of uveitis that uses interphotoreceptor retinoid binding 
protein peptide, estrogen enhanced uveitis in females, correlating with the ocular levels of Th1 
(IFN- γ) and Th2 (IL-10) cytokine messengers160. 
 Both humoral and cellular immune responses occur in EAAU. However, transfer of disease only 
occurs through CD4+ T cell transfer, and not through transfer of serum123. The expression of 
cytokines, chemokines, and adhesion molecules necessary for the development of EAAU 
requires availability and activation of complement. Interference in the availability of complement 
by systemic depletion leads to the suppression of disease146. Complement regulatory proteins 
also play an active role in the resolution of the disease by down regulating complement 
activation161. 
Cellular adhesion molecules are upregulated in EAAU. Intercellular adhesion molecule-1 
(ICAM-1), a surface glycoprotein that binds leukocyte integrins in the face of inflammation, is 
upregulated prior to detectable lymphocytic infiltration and throughout the course of 
EAAU143.  It has been proposed that uveal expression of ICAM-1 may facilitate the adherence 
and migration of immune cells into the uvea.  MHC II cell surface antigen is recognized by 
antigen presenting cells, is important in T-cell induction162, and is upregulated during EAAU 
143.  Lymphocyte function-associated antigen 1 (LFA-1) is an integrin found on lymphocytes and 
plays a key role in leukocyte emigration and cytotoxic T-cell mediated immune response. It is 
also upregulated in EAAU 143.   
Woon et al (1998) analyzed mRNA in the uvea of 5-6 week old male rats with EAAU and found 
TNFɑ gene expression levels paralleled the course of disease and that no significant changes 
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occurred in gene expression of IL -2,-4,-6, or -10 levels163. Another study evaluating the role of 
complement in EAAU, revealed IFN and IL-10 protein levels were elevated during EAAU and 
complement depleted rats had significantly reduced levels of these cytokine146. Tolerance to 
EAAU has been demonstrated though intravenous injection of MAA, and is mediated through 
the generation of T regulatory cells (Treg) which suppress T cell proliferative responses. Rats 
that developed tolerance had elevated levels of both IL-10 and transforming growth factor-2, 
whereas levels of TNF, IFN, and IL-2 were decreased. The tolerance was reversed by 
replenishing the rats with recombinant IL-2, leading the authors to conclude that tolerance was 
caused by reduced IL-2 levels164. 
 
1.6 Role of Bacterial Infections 
Molecular mimicry occurs when self-reactivity is triggered by cross-reactivity between a self-
protein and an exogenous protein that bears the same or similar amino acid sequence. Bacteria 
may serve as an exogenous protein that can trigger a molecular mimicry response in a vulnerable 
individual165. Streptococcal infection is implicated in flares or worsening of chronic disease in 
some children with JIA166.   𝛃 Hemolytic streptococcus, similar to Staphylococcus aureus also 
produces a protease, streptokinase. Streptokinase has been associated with the development of 
uveitis when administered intravenously as a thrombolytic agent in humans167. Post 
Streptococcal reactive arthritis is known to occur in humans following pharyngeal and/or 
tonsillar infection with 𝛃 hemolytic Streptococcus and a concurrent uveitis has been reported168. 
Uveitis accompanying arthritis has been observed in rats injected with various bacterial cell wall 
components including Streptococcal cell wall fragments169, and the inactivated mycobacterium 
in complete Freund’s adjuvant158. 
Infection with strains of bacteria that produce proteases like Streptococcus or Staphylococcus 
result in collagen breakdown in either the eye or joint and expose a shared antigen. The initial 
breakdown and exposure of the antigen may be facilitated by an infectious cause like 
Staphylococcal proteases or streptokinase or be mediated through endogenous proteases like 
MMP-1.  
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1.7 Role of Matrix Metalloproteinase 
MMPs are a group of zinc‐dependent extracellular enzymes that play a key role in normal and 
pathological tissue remodeling. Collagenases, a class of MMPs, are capable of degrading intact 
collagen type II, one of the main components of the articular cartilage170-171. MMP expression is 
influenced by cytokine expression172-175. Elevated serum and synovial fluid levels of MMP‐3 are 
found in patients with active polyarticular and oligoarticular JIA 176-177 and they have been 
implicated in pathologic tissue degradation in rheumatoid arthritis and osteoarthritis.  Elevated 
levels of MMPs are also found in humans with uveitis and rabbits with LPS- induced uveitis and 
are considered fundamental in the tissue destructive and repair processes178. Increased 
concentrations of MMP-2, MMP-3, and MMP-9 were observed in the aqueous of children with 
inactive JIA-uveitis compared to aqueous from eyes of children without inflammatory disease104. 
This study demonstrates that even children with clinically inactive disease likely have undetected 
ongoing pathology. 
Single nucleotide polymorphisms coding for aberrant overexpression of MMP-1 and -13 in the 
face of vacant estrogen receptors have been identified179; vacant estrogen receptors are present in 
post-menopausal and pre-menarchal females.  As discussed above, young (pre-menarchal) 
females are over represented in the JIA-uveitis population.  A role for MMP over expression in 
these patients has not been investigated.   MAA digested with MMP-1 results in a fragment of 
type 1 collagen between 20 and 25 kDa124. The uveitogenicity of this fragments has not been 
evaluated. It is possible that MMP-1, like V8 protease, could endogenously expose a shared 
pathogenic peptide between the joint and the eye.   
1.8 Research Objectives 
There are three chapters in the body of this thesis that encapsulate the objectives of this research. 
Since young onset age and female sex are two risk factors for the development of uveitis in 
children with JIA, the first manuscript of this thesis examines the influence of age and sex on 
EAAU ocular findings and pro-inflammatory cytokine levels. 
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The second manuscript describes our exploration of a common collagen trigger for autoimmune 
arthritis and uveitis in the Lewis rat. A fragment of type I collagen from bovine skin and type II 
collagen from cartilage were evaluated for antigenicity in an intact form as well as 
digested.  Three enzymes were used for collagen digestion; streptokinase, V8 protease, and 
MMP-1.  
The final manuscript in this thesis evaluates the pathogenicity of MAA digested by streptokinase, 
V8 protease and MMP-1 without the use of complete Freund’s adjuvant. 
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2.1 Abstract 
Purpose: Experimental autoimmune anterior uveitis is an established animal model for 
autoimmune anterior uveitis. Young age and female sex are risk factors for uveitis in children 
with JIA. The objectives of this research were to determine if differences occur in experimental 
autoimmune anterior uveitis between adult and juvenile and male and female rats by evaluation 
with biomicroscopic and light microscopic ocular examinations, and pro-inflammatory vitreous 
cytokine profiles. Methods: Lewis rats were inoculated with insoluble MAA. Biomicroscopic 
examinations were completed three times a week by a masked examiner. At the termination of 
the experiment, the rats were euthanized and the eyes were enucleated. Vitreous was collected 
and assayed by bead-based multiplex immunoassay for levels of 27 inflammatory cytokines.  
Globes were fixed, sectioned, processed, mounted on slides, and stained with hematoxylin and 
eosin.  Clinical uveitis scores, ocular histopathological scores, and cytokine analysis were 
compared between age and sex groups and control animals. 
Results: Rats immunized with insoluble MAA developed fibrin in their anterior chambers, 
dilation of iridal vessels and miosis. Light microscopic examination revealed a lymphocytic 
anterior uveitis in 16/16 rats and choroiditis in 12/16 rats. The average time to onset of uveitis, 
peak clinical score, and vitreal cytokine levels did not differ significantly among the differing 
age and sex groups.  
Conclusions:  No difference in disease incidence, severity, or onset was observed between sexes 
or age groups in rats inoculated with MAA.   
 
Keywords:  Autoimmune Uveitis, Cytokines, Inflammation, Melanin Associated Antigen, 
Uveitis  
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2.2 Introduction 
Chronic uveitis is among the most common debilitating extra-articular manifestation of JIA.  
Among children with JIA reported prevalence rates of uveitis range between 9.3 to 38% 1-7. A 
combination of genetic, environmental and infectious factors are speculated to play a role in the 
pathophysiology of uveitis associated with JIA8-11. There is evidence supporting autoimmune and 
pro-inflammatory processes underlying JIA-uveitis pathogenesis.  As examples, T-helper cell 
(Th)1, Th17, regulatory T cells (Tregs), and pro-inflammatory cytokines contribute to JIA-
uveitis  pathophysiology12-18. 
 Female sex and young age at onset, are two risk factors for the development of JIA-uveitis2, 19. 
Females comprise approximately 80% of children with JIA who develop uveitis20; the risk of 
developing uveitis in girls with JIA is highest in those aged 1-2 years21. Uveitis risk is not age 
dependent in boys with JIA.  Despite uveitis being more prevalent in females, only 15% of 
females with JIA present with uveitis as the initial manifestation of their disease, compared to 
44% of males22-23.  Disease severity and complication rates were also reported to vary between 
sexes; males develop more severe disease and have a higher complication rate 19-20, 22, 24-25. 
Experimental autoimmune uveitis (EAAU) is induced following injection of uveal type I 
collagen harvested from the bovine eye26-30. It manifests as a severe bilateral uveitis 
approximately 11-15.5 days post 26-30. Light microscopic examination of affected rats 
demonstrate a marked lymphocytic iritis and cyclitis 26-32. The antigen in EAAU has been 
identified as a 22 kDa fragment found in the ɑ2 chain of type 1 collagen. Most studies of EAAU 
have used 6-8 week old male rats 26-31. EAAU serves as a valuable animal model for elucidating 
pathophysiology of autoimmune anterior uveitis. The EAAU model of uveitis is a suitable model 
for JIA-uveitis as it is a predominantly anterior uveitis. The main limitation of EAAU and all 
current rodent models of uveitis is its self-limiting course.   
The objective of this study was to ascertain if rat EAAU had similar clinical and histologic 
characteristics to human JIA-uveitis.  Since young age onset and female sex are risk factors for 
development of uveitis in JIA, the objectives of this study were to compare the biomicroscopic, 
light microscopic, and vitreous inflammatory cytokine manifestations of EAAU in four age 
groups and both sexes.  
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2.3 Materials and Methods 
2.3.1 Animals 
Pathogen free male and female adult (175 day old) and juvenile (28 day old) Lewis rats were 
obtained from Charles River Laboratories (Sherbrooke, Quebec, Canada). All rats were provided 
a seven day acclimation period prior to initiation of the experiment. All procedures were 
approved by the University of Saskatchewan Animal Research Ethics Board (protocol 
20150069). Rats were housed in groups of two or three with the treatment and control animals 
intermixed. Lighting was provided in a 12-hour light:12-hour dark cycle. Rats were provided ad 
libitum feed and water. After the acclimation period, ophthalmic examinations were completed 
and the rats were inoculated with their first injection; this was considered day one of the 
experiment. Only rats with normal clinical and ophthalmologic examinations were enrolled.  
  
2.3.2 Ophthalmic Examinations 
Ophthalmic examinations were completed by a masked Diplomate ACVO. Baseline 
examinations were completed on awake manually restrained rats and included an un-dilated and 
a dilated bio-microscopic anterior segment examination (Kowa SL-17 portable slit lamp, Kowa 
Optimed Inc., Vermont Avenue, Torrance, California, USA). Following the instillation of 0.5% 
tropicamide (Alcon, Que, Canada) indirect ophthalmoscopy (Heine Omega 200; Heine 
Instruments Canada, Kitchener) was completed.  Following the baseline ocular examinations, rat 
inoculation protocols were completed and the ocular examinations were repeated three times per 
week beginning 14 days following initial inoculations until the rats were euthanized between day 
27 and 29 post primary inoculation. The masked ophthalmologist assigned a uveitis score of 0-4 
for each eye based on a previously described scale (Bora 1995).  
  
2.3.3 Melanin Associated Antigen Preparation 
Bovine globes were obtained from a local abattoir immediately following slaughter and frozen at 
-20 C until needed. Then the globes were thawed in room temperature water. The corneas, lens 
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and vitreous were removed initially and then the iris and ciliary body were dissected and placed 
in sterile tubes with sterile technique and the tissues frozen to -20 C until MAA extraction. 
Dissected iris and ciliary body from ten bovine globes were thawed and 2 to 3 mL of 1X PBS, 
pH 7.2 was added dependent on viscosity of the mixture. The mixture was homogenized using a 
tissue homogenizer. The homogenized sample was filtered through a cheese cloth into a 50 mL 
conical tube (Fisher Scientific, Mississauga, Ontario, Canada). The sample was centrifuged 
(Sorvall ST 16R centrifuge, Thermo Fisher Scientific, Waltham, Massachusetts, USA) at 4500 x 
g for 15 minutes at 4°C and the supernatant was removed from the pellet and discarded. The 
pellet was washed 3 times with 1X PBS and re-suspended in 10 mL of 1X PBS containing 2% 
Triton X-100 (Sigma Aldrich, Oakville, Ontario, Canada). The sample was incubated at room 
temperature for 3 hours at 200 rpm on an orbital shaker (Thermo Scientific Max Q200 orbital 
shaker, Thermo Fisher Scientific, Waltham, Massachusetts, USA). The sample was centrifuged 
again at 4500 x g for 15 minutes at 4°C. The supernatant was removed.  The pellet was washed 
three times with 1X PBS and re-suspended in 10mL 1X PBS containing 2% SDS (Sigma 
Aldrich, Oakville, Ontario, Canada). This sample was incubated at 37°C for 3 hours at 200 rpm. 
Following incubation the sample was centrifuged at 4500 x g for 15 minutes at room 
temperature. The supernatant was collected and its protein concentration determined. The pellet 
containing the MAA was washed three times with 1X PBS, the PBS was removed and the pellet 
was stored at -20°C.  
 
To prepare insoluble MAA for inoculation 1X PBS was added to the MAA pellet and agitated 
until fully suspended. The protein concentration of the insoluble MAA was determined using 
Bio-Rad DC protein assay. 
   
2.3.4 Experimental Animal Groups 
Four 36 day old males, four 36 day old females, four 182 day old males and four 182 day old 
females were included in the treatment group.  Rats were anesthetized with isoflurane gas 
(Halocarbon Products Corporation, River Edge, NJ, USA) by mask and inoculated with 400 μg 
insoluble MAA and an equal volume of incomplete Freund’s adjuvant administered 
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intradermally in two aliquots at the base of the tail (n=4) or in the foot pad (n=12) once on day 
one of the experiment. Ocular examinations were initiated on day 12 following inoculation and 
repeated three times per week until euthanasia on day 27-29  post inoculation. 
A negative control group consisting of two 36 day old males, two 36 day old females, one 182 
day old male and two 182 day old females were intermixed amongst the treatment groups and 
were examined and euthanized with treatment rats between days 27 and 29 of the experiment. 
 
2.3.5 Euthanasia and Sample Collection 
All rats received a lethal intraperitoneal injection of pentobarbital sodium (80 mg/kg; 54 mg/mL; 
Euthanyl Forte, Bimeda-MTC, Cambridge, Ontario, Canada). Once the palpebral reflex was 
absent trans-conjunctival enucleations were completed. Vitreous was obtained through a 
paracentesis adjacent to the optic nerve using a 30 GA needle and 1.0 mL syringe. Vitreous 
samples were stored at -80oC until analysis. 
Following vitreous collection globes were submerged in periodate-lysine-paraformaldehyde 
(PLP) fixative (Whiteland et al 1995). Following 24 hours of fixation, globes were dehydrated 
sequentially with 70% ethanol (45 minutes), 90% ethanol (45 minutes), and 100% ethanol (twice 
for 30 minutes each).  This was followed by immersion in Histo-clear (National Diagnostics, 
USA) (twice for 30 minutes). Eyes were embedded under vacuum at 54 degrees for 30 minutes 
then processed in paraffin (Whiteland et al 1995). Paraffin blocks were sectioned into 6 µm 
sections which were floated on a water bath at 40oC prior to transfer onto glass slides. Slides 
were dried and routinely stained using hematoxylin and eosin and were reviewed by a masked 
Diplomate ACVO. 
 
2.3.6 Cytokine Analysis 
Vitreous samples were analyzed using a MILLIPLEX MAP Rat Cytokine/Chemokine Magnetic 
Bead panel (Millipore, St. Charles, MO, USA) for multiplexed quantification of 27 rat cytokines, 
chemokines, and growth factors was used. The multiplexing analysis was performed using the 
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Luminex™ 100 system (Luminex, Austin, TX, USA) by Eve Technologies Corp. (Calgary, 
Alberta, Canada). The 27-plex consisted of  G-CSF, Eotaxin, GM-CSF, IL-1α, Leptin, MIP-1α, 
IL-4, IL-1β, IL-2, IL-6, EGF, IL-13, IL-10, IL-12 (p70), IFNy, IL-5, IL-17A, IL-18, MCP-1, IP-
10, GRO/KC, VEGF, Fractalkine, LIX, MIP-2, TNFα, and RANTES.  The assay sensitivities of 
these markers range from 0.3 – 30.7 pg/mL. A cubic spline regression was applied against the 
standard curve of fluorescent intensities to extrapolate concentration values. Low end of the 
standard curve values were extrapolated using a point-to-point semi-log regression as previously 
described (Masi et al 2017). 
 
2.3.7 Statistical analysis 
For all statistical comparisons, data was examined for normality and equality of variance. Data 
distribution was visualized and a Shapiro-Wilk test used to evaluate normality. Variances were 
directly compared. Where parametric data assumptions were not met, the Kruskal-Wallis test 
was used for evaluating differences between more than two groups and the Wilcoxon rank sum 
test was used to compare two groups. The level of significance was set to 0.05. For 
cytokine analyses two comparisons were completed. The first analysis compared observed 
cytokine levels of each cytokine in all IMMA treated rats to control rats. To account for multiple 
comparisons an individual comparison significance level was calculated using a Bonferroni 
correction. The individual comparison significance level used was 0.0019 (0.05/27; 27 
cytokines). The second analysis was between the age and sex group. A Shapiro-Wilk test 
indicated unequal variance and the sample size was too small to determine distribution. A 
Kruskal-Wallis equity of populations rank test was completed with the level of significance set to 
0.05.  
All statistical analyses were completed using a commercial statistics package (STATA 15, 
StataCorp. 2017. Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC). 
 
 
35 
 
2.4 Results 
 
2.4.1 Control Groups: 
Uveitis or other ocular abnormalities were not detected in control rats clinically or with 
histologic examination.  
 
2.4.2 IMAA Treatment Group: 
Biomicroscopic Examination: 
All 16 rats inoculated with insoluble MAA developed uveitis on biomicrooscopic examination. 
The uveitis was characterized by dilation and engorgement of the iridial vessels, fibrin in the 
anterior chamber, miosis and dyscoria. Uveitis was bilateral in 15/16 rats and unilateral in one 
adult male rat.  The average exam score on each exam date with 95% confidence intervals are 
shown in Figure 3.1. Peak uveitis occurred in all treatment groups on day 21. Uveitis severity 
decreased in all treatment groups following day 21; however, uveitis persisted in all at the final 
examination. Average onset of uveitis post-inoculation was 16.25 days in juvenile females, 16.75 
days in juvenile males, 17.5 days in adult females and 20 days in adult males (Table 3.1). A 
Kruskal- Wallis analysis revealed no significant differences (p=0.4054) in uveitis onset. Average 
onset of uveitis in adult rats was 18.75 days, while average onset in all juvenile rats was 16.86 
days. This difference was not significant (p=0.2439). Average onset of uveitis in male rats was 
18.75 days, while average onset in female rats was 17.21 days. This difference was not 
significant (p=0.2439).  Uveitis was rated severe (4/4) in each eye of all rats by day 21 post-
inoculation except in two adult males and one juvenile male. One adult male only developed 
unilateral uveitis at day 26 and was graded 0.5. A second adult male and the juvenile male both 
developed grade 4/4 in one eye and a grade 3/4 in the fellow eye.  All three of these rats were in 
the foot pad injection group. 
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Figure 2- 1. A) Melanin associated antigen inoculated rats developed fibrin in their anterior 
chamber (arrow), miosis, pupillary occlusion and engorgement of iridial vessels. B) Naïve rat 
with normal anterior segment. 
 
A
 
B
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Figure 2- 2. The average clinical sore of each group with 95% confidence intervals between day 
12 post inoculation and day 26. JF= juvenile female, AF=adult female, JM=juvenile male, 
AM=adult male. 
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Table 2-1: Average days post-inoculation for onset of uveitis in each group, and compared 
between sexes and age groups. 
 
Group Average Onset (days) p 
Juvenile Female 16.25 0.4054 
Juvenile Male 16.75 
Adult Female 17.5 
Adult Male 20 
Adults 18.75 0.2439 
Juvenile 16.86 
Males 18.75 0.2439 
Females 17.21 
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Light Microscopic Examination 
All rats in the IMAA treatment group were confirmed histologically with severe lymphocytic 
iriditis and cyclitis (Figure 3B). A lymphocytic choroiditis was present in 14/16 rats (Figure 3D).  
One adult male rat had a unilateral choroiditis, while another adult male did not have choroidal 
inflammation in either eye. Control rats did not have inflammatory infiltrate in their iris, ciliary 
body, or choroid (Figure 3A and C). 
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Figure 2- 3. Light microscopy of normal control iris and ciliary body (A) and choroid (C) 
compared to iris and ciliary body (B) and choroid (D) of a rat inoculated with intact melanin 
associated antigen. The black arrow points to the choroid. The intact melanin associated antigen 
inoculated rat has a marked lymphocytic choroidal infiltration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
A
 
B
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Cytokines 
 Concentrations for 27 pro-inflammatory cytokines in the vitreous of IMAA treated rats 
compared to control rats are presented in Table 3.2 and Figure 3.4 A and B. The box and whisker 
charts Figure 3.4 A and B represent cytokines with values between 0 and 100 pg/µL (A), and 0 
and 1500 pg/µL (B). There were no statistical differences between treatment and control levels 
when corrected for multiple comparisons (Table 3.2). 
The cytokine levels for each age/sex group are presented in Figure 3.5 A and B.  Figure 3.5 A 
and B represent cytokines with values between 0 and 100 pg/µL (A), and 0 and 1000 pg/µL (B). 
Despite the lack of power with the small sample size, for completeness statistical comparisons 
were made at the level of the group to evaluate for any differences related to age of sex. There 
was no statistically significant difference between groups for any of the 27 cytokines. 
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 Figure 2- 4 A and B. Concentration of pro-inflammatory cytokines in the vitreous of control 
(white) and intact melanin associated antigen (grey) inoculated rats with values between 0 and 
100 pg/µL (A) and 0 and 1500 pg/µL (B). Outliers are indicated by dots.  
A 
B 
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Figure 2- 5 A and B. Concentration of  pro-inflammatory cytokines with values between 0 and 
100 pg/µL (A) and 0 and 1000 pg/uL (B) in the vitreous of juvenile male (dark grey), juvenile 
female (dark blue), adult male (light grey), and adult female (light blue) intact melanin 
associated antigen inoculated rats. 
A 
B 
44 
 
Table 2-2: Vitreous cytokine means, standard deviations, and p values for controls and IMAA 
treated rats. Wilcoxon rank sum analysis revealed three significant values however to account for 
multiple comparisons using a Bonferroni correction an individual 
 
 
 
 
45 
 
2.5 Discussion 
Insoluble MAA inoculations in this study demonstrated a similar incidence, onset, peak as with 
previous studies26-32. This is the first experiment to compare manifestations of the uveitis 
between adult and juvenile and male and female rats.  Juvenile female rats had the earliest onset 
of disease. The onset between the age/sex ranged from 16.25 days to 20 days which was similar 
to other reports at 15 +/- 3 days26-32. Statistical significance was not achieved as these 
comparisons lacked the necessary power to determine statistical differences of modest 
magnitude.  
This was the first report of vitreous cytokine levels in experimental autoimmune anterior uveitis. 
Woon et al analyzed mRNA in uveal tissue from rats with EAAU and found TNFɑ gene 
expression paralleled the course of disease33. They also found no change in expression of  IL-2,-
4,-6, or -10 consistent with the results in our study33. The change in TNF expression observed by 
Woon et al was not observed in our study and may be explained by our collection of vitreous in 
the late stages when the uveitis was resolving, or differences between cytokine gene expression 
in the uvea and cytokine immune assay in the vitreous. In addition to the cytokines evaluated by 
Woon et al we evaluated granulocyte-colony stimulating factor, eotaxin, granulocyte-
macrophage colony stimulating factor 2, IL 1ɑ, leptin, macrophage inflammatory protein 1a, IL 
1ꞵ, epidermal growth factor, IL 13, IL 12p70, IL 5, IL 17a, IL 18, monocyte chemoattractant 
protein-1,interferon gamma induced protein 10,GRO/KC, vascular endothelial growth factor, 
fractalkine, LIX, macrophage inflammatory protein 2, regulated on activation t cell expressed 
and secreted.  
Fang et al evaluated mRNA expression of CX3C chemokine, fractalkine, and its receptor 
CX3CR1 in the iris and ciliary body in rats inoculated with MAA. Fractalkine regulates adhesive 
and chemoattractant leukocyte functions and is preferentially expressed on Th1 cells34. Fang et al 
found fractalkine levels were elevated nine days following inoculation and preceding disease 
onset34.  Expression of fractalkine receptor, CX3CR1, peaked with the disease onset at day 14. 
Following day 14 its levels were no longer statistically different from control rats34. We did not 
see any difference in fractalkine between inoculated rats and controls in our study, likely due to 
the later harvest of vitreous. Another key difference between studies was Fang’s use of complete 
Freund’s adjuvant.  
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A limitation of our study was the single time point utilized for tissue and vitreous harvesting. 
This prevented observation of the dynamic inflammatory process throughout the course of EAAU. 
Cytokine levels at varying time points would be valuable to establish a sequence of inflammatory events 
and the components that play a role in the signaling cascade in EAAU rather than a single point of 
reference in the late stage of disease. 
 RANTES expressed and secreted was elevated, albeit non significantly, in IMMA inoculated rats 
compared to controls. RANTES is a mononuclear chemoattractant capable of influencing migration of 
CD4 T cells to inflammatory sites. It is constitutively expressed in resting T cells and following activation 
recruits more T lymphocytes to the site of inflammation. Fang et al  found RANTES aqueous 
concentrations significantly elevated between day 11 and 30 post inoculation35. The peak of 
approximately 4000pg/ml occurred on day 14, with a statistically significant elevation over 
controls persisting to day 3035.  These levels were higher than what was observed in our study of 
100pg/ml. Differences may be due to their use of complete Freud’s adjuvant at the time of MAA 
inoculation as well as differences in aqueous vs vitreous concentrations. Fang also found 
elevations in MCP-1, MIP-1, IL-8, and IP-10 mRNA levels35. These elevations were all seen up 
until either day 14 or 18, then levels declined to concentrations that we not different from 
controls35. In our study both IP-10 and RANTES levels varied between age and sex group 
however statistical significance was not reached. The limited number of subjects per treatment 
group in our study in combination with the large number of factors evaluated made reaching 
statistical significance unlikely with only modest differences between groups.  
 
For the first time, this study demonstrated the antigenicity of IMAA when injected at the base of 
the tail. This site has not been reported in the past for IMAA injections but is commonly used for 
bovine type II collagen in collagen induced arthritis. This location is superior to the traditional 
sMAA site of the foot pad especially when lower limbs are concurrently under evaluation for 
arthritis.   
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Conclusions 
Juvenile female rats had an earlier but non-significant onset of disease. Vitreous cytokine values 
are described for juvenile male, juvenile female, adult male, and adult female rats inoculated 
with intact MAA.  
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3.1 Abstract 
Objective: The pathogenesis and etiology of JIA uveitis is poorly understood.  The purpose of 
this research is to explore the potential of a shared collagen based self-antigen existing between 
the joint and eye in the pathogenesis of JIA-uveitis.  
Methods: Adult and juvenile male and female Lewis rats were inoculated intradermally with 
either: intact Staphylococcal V8 protease solubilized or matrix metalloproteinase (MMP)-1 
solubilized type I collagen derived from bovine skin, or II collagen derived from bovine 
cartilage. Inoculations were repeated up to two times at intervals of 1 or 4 weeks. 
Biomicroscopic and indirect ophthalmoscopic examinations were completed in live rats at 
baseline and biomicroscopic examinations were repeated three time per week throughout the 
study period by a masked Diplomate of the American College of Veterinary Ophthalmologists 
(ACVO). At the end of the observation period globes were enucleated and vitreous was 
aspirated. Histopathology slides of the globes were reviewed by a masked Diplomate ACVO. An 
array of 27 cytokines were quantified with a multiplex bead-based immunoassay on vitreous 
from rats treated with MMP-1 digested type I or type II collagen.   
 Results: None of the rats in this study developed uveitis that could be detected clinically or light 
microscopically. 28/44 rats inoculated with intact type II collagen developed arthritis. Rats 
inoculated with either Staphylococcal V8 protease solubilized, or MMP-1 solubilized type II 
collagen did not develop arthritis. Vitreous cytokine levels did not differ between treatment 
groups and controls.  
Conclusions:  Intact or MMP-1, Staphylococcus V8 protease digestions of type I or type II 
collagen did not result in uveitis in the Lewis rat. Digestion of type II collagen renders it non-
pathogenic. 
Funding: Jim Pattison Children’s Hospital Foundation 
  
53 
 
3.2 Introduction 
JIA is the most common form of chronic arthritis in children and uveitis is the most common 
debilitating extra-articular manifestation of JIA1. Little is known about the underlying 
pathophysiology linking the ocular and joint inflammation2-5. 
Currently, there are limited reports of animal models for JIA-uveitis. Uveitis and arthritis have 
been reported in female Sprague-Dawley rats inoculated with type II collagen6.  Type II collagen 
inoculation is a well-established rodent model of arthritis used for investigating arthritis 
pathogenesis, and potential therapies7. Uveitis has also been documented in a 1/15 rats receiving 
spleen cells from rats inoculated with type II collagen8.  
 Collagens are typically highly conserved proteins, although some tissue-specific structural 
differences have been identified9-10.  Type I collagen is the most abundant collagen in the body 
and is the main structural component of bones, tendons and ligaments11. Almost 50 different 
molecules that interact with type I collagen have been recognized, including sequences for 
integrins12-17, Il-218, Staphylococcus aureus cell surface molecules19, Staphylococcus aureus 
matrix binding proteins20, MMPs21 and many others11. 
  Experimental autoimmune uveitis (EAAU) is a severe bilateral uveitis in the Lewis rat that 
occurs in response to inoculation with a 22 kDa α chain fragment of type I collagen22-26. The 
antigen is harvested from bovine uvea, and its soluble form is isolated following digestion with 
Staphylococcus aureus V8 protease. The role of V8 protease in development of the antigenic 22 
kDa fragment of type I collagen may implicate protease involvement in exposure of the antigenic 
peptide in vivo.  
MMPs are a group of zinc dependent extracellular enzymes that play a key role in normal and 
pathological tissue remodeling. Collagenases, a class of MMPs, are capable of degrading intact 
collagen type II, one of the main components of the articular cartilage27-28. Elevated serum and 
synovial fluid levels of MMP‐3 are found in patients with active polyarticular and oligoarticular 
JIA29-30 and they have been implicated in pathologic tissue degradation in rheumatoid arthritis, 
and osteoarthritis. Increased concentrations of MMP-2, MMP-3, and MMP-9 have been observed 
in the aqueous of children with inactive JIA-uveitis compared to aqueous from eyes of children 
without inflammatory disease31. Uveal tissue digested with MMP-1 results in fragments of type 1 
54 
 
collagen between 20 and 25 kDa26; this is similar in size to the 22 kDa fragment known to cause 
uveitis in EAAU22-26. 
 Type I collagen from bovine skin, Achilles tendon, and rat tail have been tested in their intact 
form as well as following digestion with V8 protease and were not uveitogenic25. Type I collagen 
derived from bovine skin, and type II collagen derived from bovine cartilage, digested with 
MMP-1 have not been evaluated for uveitogenicity.  
The purpose of this study was to explore a common collagen trigger for autoimmune arthritis and 
uveitis in the Lewis rat. Commercially available purified type I collagen isolated from bovine 
skin (Chondrex, Redmond, VA, USA) and bovine type II collagen derived from fetal bovine 
articular cartilage (mdBioproducts, St Paul, MN) were evaluated in an intact form, and following 
digestion with either V8 protease or MMP-1.  
 
Materials and Methods 
3.2.1 Animals 
Pathogen free male and female adult (175 day old) and juvenile (28 day old) Lewis rats were 
obtained from Charles River Laboratories (Sherbrooke, Quebec, Canada). All rats were provided 
a seven day acclimation period prior to initiation of the experiment. All procedures were 
approved by the University of Saskatchewan Animal Research Ethics Board (protocol 
20150069). Rats were housed in groups of two or three with the treatment and control animals 
intermixed. Lighting was provided in a 12 hour light: 12 hour dark cycle. Rats were provided ad 
libitum feed and water. After the seven day acclimation period ophthalmic examinations were 
completed and rats were inoculated with their first injection; this was considered to be day one of 
the experiment.  
 
3.2.2 Ophthalmic Examinations 
Ophthalmic examinations were completed by a masked Diplomate ACVO on awake, manually 
restrained rats. These examinations included an un-dilated and a dilated biomicroscopic anterior 
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segment examination (Kowa SL-17 portable slit lamp, Kowa Optimed Inc., Vermont Avenue, 
Torrance, California, USA). Following the instillation of 0.5% tropicamide (Alcon, Que, 
Canada) indirect ophthalmoscopy (Heine Omega 200; Heine Instruments Canada, Kitchener) 
was completed.  Rats were excluded from the experiment if any intraocular inflammation or 
ophthalmic abnormalities were detected. 
Following baseline ocular examinations, rat inoculation protocols were initiated and rats were re-
examined three times per week beginning 14 days following initial inoculation and repeated until 
euthanasia. At repeat examinations uveitis was assigned a score of 0-4 based on previously 
described scales32. When a uveitis score of >0 was assigned, posterior segment examination was 
repeated. At each examination, examiner, uveitis score, flare score, and ocular abnormalities 
were recorded.  
3.2.3 Reconstitution of Type I and Type II collagen: 
Lyophilized Type I and Type II collagen (Chondrex, Redmond, VA, USA) were reconstituted 
with 0.05M Acetic Acid to 2.0 mg/ml and left overnight at 4°C with constant stirring. 
 
3.2.4 Staphylococcus aureus V8 digestions 
2.5 mL of Type I or Type II collagen were added to a conical tube containing 7.5 mL of 8M urea 
(EMD Millipore, Etobicoke, Ontario, Canada), 1.125mL of 1M potassium phosphate buffer, 1 
mL of 1,500 unit Endoproteinase Glu-C from Staphylococcus aureus V8 (Sigma Aldrich, 
Oakville, Ontario, Canada) and 2.875 mL of double distilled water (Milli-Q Advantage A10 
System, EMD Millipore, Etobicoke, Ontario, Canada) to yield final concentrations of 4M urea, 
75mM potassium phosphate buffer and 100 units of Endoproteinase Glu-C from Staphylococcus 
aureus V8. The sample was incubated on an orbital shaker at 37° at 200 rpm for 30 minutes. 
Following incubation, the tubes were placed in a beaker of boiling water for two minutes to 
inactivate the V8 protease. The sample was centrifuged at 4,500 x g for 20 minutes at 4°C. The 
supernatant was collected and dialyzed against double distilled water (Milli-Q, EMD Millipore, 
Etobicoke, Ontario, Canada) using 3.5K MWCO Dialysis Membrane (Thermo Fisher Scientific, 
Waltham, Massachusetts, USA) for 48 hours with water changes every 2 hours for the first 10 
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hours and every 4 hours for the remainder of time. The sample was transferred to a 50 mL 
conical tube (Fisher Scientific, Mississauga, Ontario, Canada) and frozen at -80°C. Once frozen, 
the sample was lyophilized (FreeZone Plus 6 Liter Cascade Console Freeze Dryer, Labconco, 
Kansas City, Missouri, USA) for approximately 48 hours or until lyophilized. The lyophilized 
sample was stored at -20°C until ready for use. Prior to use, the lyophilized sample was 
dissolved in 1 mL of 1X PBS, pH 7.2 and protein concentration was determined using Bio-Rad 
DC Protein Assay (Bio-Rad Laboratories, Hercules, California, USA). 
 
3.2.5 Matrix Metalloproteinase-1 digestions 
Prior to use, the MMP-1 (EMD Millipore, Etobicoke, Ontario, Canada) was activated with 
trypsin (Trypsin from Bovine Pancreas, EMD Millipore, Etobicoke, Ontario, Canada) at a ratio 
of 10:1 MMP-1 to trypsin for 10 minutes at 25°C. The trypsin was inactivated with a 10-fold 
excess of soybean trypsin inhibitor (EMD Millipore, Etobicoke, Ontario, Canada). The 2.5 mL of 
type I or type II collagen was added to a conical tube containing 7.5 mL of 8M urea (EMD 
Millipore, Etobicoke, Ontario, Canada), 1.125mL of 1M potassium phosphate buffer, 0.60 mL of 
50 µg/mL MMP-1 (EMD Millipore, Etobicoke, Ontario, Canada) and 3.275 mL of double 
distilled water (Milli-Q EMD Millipore, Etobicoke, Ontario, Canada) to yield final 
concentrations of 4M urea, 75mM potassium phosphate buffer and 2 µg/mL of MMP-1. The 
sample was incubated on an orbital shaker at 25°C at 200 rpm for 30 minutes. Following 
incubation, the reaction was stopped with 50 mM EDTA. The sample was centrifuged at 4,500 x 
g for 20 minutes at 4°C. Dialysis and lyophilization of the sample was completed. 
 
3.2.6 Treatments 
Rats were anesthetized using isoflurane gas (Halocarbon Products Corporation, River Edge, NJ, 
USA) provided through a flow by mask.  The type I collagen used in the inoculations was 
commercially available purified type I collagen isolated from bovine skin (Chondrex, Redmond, 
VA, USA). Type II collagen was commercially available bovine type II collagen derived from 
fetal bovine articular cartilage (mdBioproducts, St Paul, MN). The dose for all intact and 
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digested inoculations was 400µg. The inoculations were administered in an equal volume of 
incomplete Freund's adjuvant (Sigma, Oakville, Ontario, Canada) in two aliquots at the base of 
the tail.  
3.2.7 Control Animals:  
Two control groups were used. A negative control group consisting of 8 naive rats and a second 
group of 8 rats inoculated with only incomplete Freund’s adjuvant once at the beginning of the 
experiment were intermixed amongst all treatment groups and euthanized alongside treated rats. 
 
3.2.8 Single inoculations 
The following inoculations were administered to 2-5 rats of each age and sex cohort once at the 
beginning of the experiment: Intact type I collagen, intact type II collagen, V8 digested type I 
collagen, MMP-1 digested type I collagen, and MMP-1 digested type II collagen.  
3.2.9 Repeated inoculations: short interval 
The following inoculations were administered to 1-4 rats of each age and sex cohort at the 
beginning of the experiment and again 7 days later: Intact type II collagen, V8 digested type I 
collagen, V8 digested type II collagen. 
3.2.10 Repeated inoculations: long interval 
The following inoculations were administered to 2-4 rats of each age and sex cohort at the 
beginning of the experiment and again 28 days later: Intact type II collagen 
 
3.2.11 Euthanasia and Tissue Collection 
Rats were euthanized between day 33 and 57. All rats received a lethal intraperitoneal injection 
of pentobarbital sodium (80 mg/kg; 54 mg/mL; Euthanyl Forte, Bimeda-MTC, Cambridge, 
Ontario, Canada). Sub-conjunctival enucleation was completed and globes were immediately 
submerged in periodate-lysine-paraformaldehyde (PLP) fixative33. Following 24 hours of 
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fixation globes were processed using previously described methods33. Paraffin blocks were 
sectioned into 6 µm sections which were floated on a water bath at 400C prior to transfer onto a 
glass slide. Slides were dried and stained using hematoxylin and eosin stain. Histopathology 
slides were reviewed by a masked Diplomate ACVO and diagnosed and graded for uveitis by the 
previously cited grading scheme or designated as normal. 
3.2.12 Cytokine Analysis 
 Vitreous samples collected from rats treated with MMP-1 digested Type I and MMP-1 digested 
Type II collagen were analyzed for cytokine/chemokine profiling. In this study, Luminex xMAP 
technology for multiplexed quantification of 27 cytokines, chemokines, and growth factors for 
rats were utilized. The multiplexing analysis was performed using the Luminex™ 100 system 
(Luminex, Austin, TX, USA) by Eve Technologies Corp. (Calgary, Alberta, Canada). Twenty-
seven markers were simultaneously measured in the samples using a MILLIPLEX Rat 
Cytokine/Chemokine 27-plex kit (Millipore, St. Charles, MO, USA) according to the 
manufacturer's protocol.  The 27-plex consisted of  granulocyte-colony stimulating factor (G-
CSF), Eotaxin, granulocyte-macrophage colony stimulating factor (GM-CSF), IL-1α, Leptin, 
macrophage inflammatory protein 1a (MIP-1α), IL-4, IL-1β, IL-2, IL-6, epidermal growth factor 
(EGF), IL-13, IL-10, IL-12 (p70), IFNy, IL-5, IL-17A, IL-18, monocyte chemoattractant protein-
1 (MCP-1), interferon gamma induced protein 10 (IP-10), human growth-regulated 
oncogene/keratinocyte chemoattractant (GRO/KC), vascular endothelial growth factor (VEGF), 
Fractalkine, Lipopolysaccharide-inducible CXC chemokine (LIX), macrophage inflammatory 
protein 2 (MIP-2), tumor necrosis factor ɑ (TNFα), and regulated on activation T cell expressed 
and secreted (RANTES).  The assay sensitivities of these markers range from 0.3 – 30.7 pg/mL 
for the 27-plex.   
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3.3 Results 
3.3.1 Ophthalmic evaluations 
None of the rats in these experiments developed uveitis based on biomicroscopic and histologic 
examinations. 
3.3.2 Joint Evaluations 
The overall incidence of arthritis in intact type II collagen treated rats was 28/44. Of the rats 
inoculated with one injection, two injections 7 days apart, or two injections 28 days apart 5/12, 
8/16, and 15/16 developed arthritis. The rate of arthritis at the cohort level per inoculation 
schedule is provided in table 1.  
Rats inoculated with either V8 protease or MMP-1 digested type II collagen did not develop 
arthritis. 
None of the rats inoculated with either digested or intact type I collagen developed arthritis. 
Naïve and IFA inoculated rats did not develop arthritis. 
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Table 3-1: Arthritis and uveitis outcomes for each treatment group receiving intact type II 
collagen listed by the age and sex grouping. 
Inoculation Schedule Total Arthritis Uveitis 
One Inoculation 
   
Adult Male  3 3 0 
Juvenile Male  3 0 0 
Adult Female  3 2 0 
Juvenile Female  3 0 0 
Two Inoculations; 1 week apart 
   
Adult Male  4 2 0 
Juvenile Male  4 1 0 
Adult Female  4 4 0 
Juvenile Female  4 1 0 
Two Inoculations; 4 weeks apart 
   
Adult Male  4 4 0 
Juvenile Male  4 3 0 
Adult Female  4 4 0 
Juvenile Female  4 4 0 
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3.3.3 Cytokine Evaluation 
The vitreous cytokine profiles of rats inoculated with MMP-1 digested type I or II collagen did 
not differ from controls (Figure 3-1 A and B). 
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Figure 3- 1  A and B.  Vitreal cytokine concentrations of 27 cytokines from the vitreous of rats 
inoculated with either type I or type II collagen digested in matrix metalloproteinase 1 compared 
to naive rats. The dots represent outliers. Abbreviations: T1MMP: type 1 collagen digested with 
matrixmetalloproteinase-1, T2MMP: type 2 collagen digested with matrix metalloproteinase-1. 
A 
B 
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3.4 Discussion 
Bovine type I or type II collagen administered intact or following digestion with MMP-1 or V8 
protease did not induce uveitis in this investigation. As expected, intact type II collagen 
inoculation resulted in arthritis in 28/44 rats. None of these rats developed uveitis. This was in 
contrast to a report by Petty et al6 in which clinical uveitis was reported in 4/40 female Sprague-
Dawley rats inoculated. Two of these rats had concurrent arthritis while two demonstrated uveitis 
as their only pathology6. Uveitis has also been documented in a 1/15 rats receiving spleen cells 
from rats inoculated with type II collagen8. The difference may be related to differences in 
genetic susceptibility between Lewis and Sprague-Dawley rats, dose, concurrent arthritis, or 
injection schedule. Petty et al administered 200 ug on day 1 and day 7 in the hind foot pad6, 
while we administered 400 ug at the base of the tail either once, twice a week apart or twice four 
weeks apart.  
Rats treated with type II collagen digested in either V8 protease or MMP-1 did not develop 
arthritis or uveitis.  Possible explanations for the loss of antigenicity of type II collagen following 
digestion is loss of the antigenic epitope on the collagen or the single injection did not provide 
sufficient antigenic stimulation. Of the rats that were inoculated with only one injection of intact 
type II collagen 5/12 developed arthritis, compared to 8/16 receiving two injections one week 
apart or 15/16 receiving two injections one week apart. If the former speculation for loss of 
antigenicity is correct, then MMP-1 would have a protective role in vivo. 
  
A single injection of intact, V8 protease digested or MMP-1 digested bovine type I collagen 
failed to induce uveitis. A previous report25 found intact type I collagen isolated from bovine 
skin, Achilles tendon, and rat tail was not pathogenic, nor was V8 protease treated skin derived 
type I collagen. The study also evaluated MAA, an agent known to cause uveitis, and found 
deglycosylation of glycoproteins rendered it non-pathogenic. These authors concluded that the 
antigenic properties of type 1 collagen α-2 chain were specific to uveal collagen post-
translational carbohydrate moieties25.  
This was the first investigation of the pathogenicity of MMP-1 digested collagen. MMP-1 
digestions of both type I and II collagen derived from bovine skin and cartilage respectively, did 
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not induce uveitis. Furthermore, digestion of type II collagen with MMP-1 rendered it incapable 
of inducing arthritis. 
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4.1 Abstract 
Purpose: Experimental autoimmune anterior uveitis is induced with a 22 kDa fragment of type I 
collagen located on the α2 chain. It is isolated from MAA using Staphylococcal V8 protease. It is 
known to induce uveitis when administered in conjunction with complete Freund adjuvant 
(CFA). The purpose of this study was to determine the pathogenicity of MAA following 
digestion with either Staphylococcal v8 protease, streptokinase C, or matrix metalloproteinase-1 
(MMP-1) administered without the use of CFA. 
Methods: Lewis rats were inoculated with MAA that was solubilized with either Staphylococcus 
aureus V8 protease, Streptococcus streptokinase C, or MMP-1. Injections were repeated three 
times one week apart. Biomicroscopic examinations were completed three times per week until 
the termination of the experiment. Clinical uveitis scores and immunohistochemical labels for 
CD43 and CD45RC were compared between treatment groups and control animals. 
Results: Uveitis was present in 3/12 Staphylococcus aureus V8 protease inoculated rats. All 
three were confirmed clinically and two were confirmed with light microscopy. Uveitis was 
present in 2/12 streptokinase C solubilized MAA inoculated rats. One rat confirmed clinically, 
and one was confirmed on light microscopy. None of the rats inoculated with MMP-1 digested 
MAA developed uveitis clinically or with light microscopy. 
Conclusions:  Streptococcus streptokinase C and Staphylococcus aureus V8 protease digested 
MAA induced uveitis in some rats when inoculations are repeated three times without the use of 
CFA.  
Funding: Jim Pattison Children’s Hospital Foundation of Saskatchewan 
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4.2 Introduction 
Autoimmune uveitis is a common potentially blinding ocular inflammatory diseases. It affects 
between 17 and 52 per 100 000 people per year and it is implicated in 25% of legal blindness in 
the developing world1. Uveitis can be a result of inflammation isolated to the eye or can occur as 
a manifestation of a multi-system disease. The etiopathogenesis of autoimmune uveitis is not 
clearly understood but multiple factors including infectious triggers and genetic vulnerability 
have been implicated2-5. Loss of self-tolerance in autoimmune disease can occur through 
molecular mimicry, where infectious determinants mimic host antigens and trigger self -reactive 
T cell clones that destroy host tissue6.  The normal immune privilege of the eye prevents 
peripheral autoreactive lymphocytes from acquiring tolerance to normal ocular tissues. When the 
blood-ocular barrier is compromised T lymphocytes may become primed to recognize ocular 
antigens7. 
 
Experimental autoimmune anterior uveitis (EAAU) is a rodent model of anterior uveitis induced 
with inoculation of soluble MAA8-12.  MAA is derived from uveal tissue, typically bovine-
derived, that has been digested with Staphylococcal aureus V8 protease8-12. Staphylococcus 
aureus V8 protease digested rat (autologous) MAA has been shown to induce uveitis12. The 
antigen in EAAU has been identified as a 22kDa fragment found in the ɑ2 chain of type 1 
collagen and immunohistochemistry of naive rats has demonstrated the presence of endogenous 
MAA in the normal iris and ciliary body12. 
EAAU manifests as severe bilateral anterior uveitis approximately 11-15.5 days post inoculation 
in nearly all rats inoculated8-12. The uveitis is mediated through an antigen specific CD4 + T cell 
response8-15. Light microscopic examination of immunohistochemistry slides of affected rats 
demonstrate a marked CD4+ T cell infiltration of the anterior uvea8-15. Soluble MAA has only 
induced uveitis when administered with complete Freund’s adjuvant, which contains inactive 
mycobacteria known to stimulate cell-mediated immunity, tumor necrosis factor dysregulation, 
and uveitis16-19. Incomplete Freund’s adjuvant provides a water-oil emulsion to facilitate 
inoculation administration without immunostimulation.  
 
β Hemolytic Streptococcus, similar to Staphylococcus aureus, also produces a protease, 
streptokinase C. Streptokinase alone has been associated with the development of uveitis when 
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administered intravenously as a thrombolytic agent in humans20.  People with post-streptococcal 
reactive arthritis following pharyngeal and/or tonsillar infection with 𝛃 hemolytic Streptococcus 
have also been reported to developed uveitis21. Uveitis accompanying arthritis has also been 
observed in rats injected with various bacterial cell wall components including Streptococcal cell 
wall fragments22. To our knowledge the uveal pathogenicity of Streptokinase C digested MAA 
has not been evaluated in animal models. 
Matrix metalloproteinases (MMPs) are endogenous proteases capable of lysing type I, II, III and 
X collagens. They are present in normal human iris, ciliary epithelium, uveoscleral outflow 
pathway and corneal endothelium23. Digestion of MAA with MMP-1 in vitro results in several 
collagen fragments between 20 and 25 kDa, which are similar to the molecular mass of MAA of 
22 kDa12 suggesting MMP-1 may  play a role in MAA generation in vivo12. In rats with EAAU 
mRNA levels of MMP-1 increase significantly at day 11 post immunization and peak coinciding 
with peak uveitis  at day 19 and then decline12. 
 
The objective of this study was to explore possible mechanisms of MAA exposure in vivo by 
evaluating the pathogenicity of MAA following proteolysis with V8 protease, streptokinase C, 
and MMP-1, without the use of complete Freund’s adjuvant, in juvenile female Lewis rats. 
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4.3 Materials and Methods 
4.3.1 Animals 
Pathogen free female juvenile (28 day old) Lewis rats were obtained from Charles River 
Laboratories (Sherbrooke, Quebec, Canada). All rats were provided a seven day acclimation 
period prior to initiation of the experiment. All procedures were approved by the University of 
Saskatchewan Animal Research Ethics Board (protocol 20150069). Rats were housed in groups 
of two or three with the treatment and control animals intermixed. Lighting was provided in a 12 
hour light: 12 hour dark cycle. Rats were provided ad libitum feed and water. After the 
acclimation period ophthalmic examinations were completed and the rats were inoculated with 
their first injection; this was considered to be day one of the experiment. 
  
4.3.2 Ophthalmic Examinations 
Ophthalmic examinations were completed by a Diplomate ACVO masked to the treatment 
groups. Baseline examinations were completed on awake manually restrained rats and included 
an un-dilated and a dilated bio microscopic anterior segment examination (Kowa SL-17 portable 
slit lamp, Kowa Optimed Inc., Vermont Avenue, Torrance, California, USA). Following the 
instillation of 0.5% tropicamide (Alcon, Que, Canada) indirect ophthalmoscopy (Heine Omega 
200; Heine Instruments Canada, Kitchener) was completed.  Rats were excluded from the 
experiment if there were detected ophthalmic abnormalities. 
Following baseline examination, rat inoculation protocols were completed and rats were re-
examined three times per week beginning 14 days following initial inoculation and repeated until 
euthanasia. At repeat examinations the masked examiner assigned a score of 0-4 for both the 
uveitis and flare based on previously described scales24. When a uveitis score of >0 was assigned 
the posterior segment examination was repeated at each examination thereafter. For each 
examination the examiner, uveitis score, flare score, ocular abnormalities were recorded and 
each eye was photographed. Rats were euthanized on days 26, 28, 36 or 42 post primary 
inoculation.  
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4.3.3 Melanin Associated Antigen Preparation 
Iris-Ciliary Body Dissection for MAA 
Bovine globes were obtained from a local abattoir immediately following slaughter and frozen 
until use. Globes were thawed in room temperature water. The corneas, lens and vitreous were 
removed. Using sterile instruments the iris and ciliary body were dissected and placed in sterile 
tubes and frozen at -20 until MAA extraction. 
  
MAA Extraction 
Dissected iris and ciliary body from ten bovine globes were thawed and 2 to 3 mL of 1X PBS, 
pH 7.2 was added dependent on viscosity of the mixture. The mixture was homogenized using a 
tissue homogenizer. The homogenized sample was filtered through a cheese cloth into a 50 mL 
conical tube (Fisher Scientific, Mississauga, Ontario, Canada). The sample was centrifuged 
(Sorvall ST 16R centrifuge, Thermo Fisher Scientific, Waltham, Massachusetts, USA) at 4500 x 
g for 15 minutes at 4°C and the supernatant was removed from the pellet and discarded. The 
pellet was washed 3 times with 1X PBS and re-suspended in 10 mL of 1X PBS containing 2% 
Triton X-100 (Sigma Aldrich, Oakville, Ontario, Canada). The sample was incubated at room 
temperature for 3 hours at 200 rpm on an orbital shaker (Thermo Scientific Max Q200 orbital 
shaker, Thermo Fisher Scientific, Waltham, Massachusetts, USA). The sample was centrifuged 
again at 4500 x g for 15 minutes at 4°C. The supernatant was discarded.  The pellet was washed 
three times with 1X PBS and re-suspended in 10mL 1X PBS containing 2% SDS (Sigma 
Aldrich, Oakville, Ontario, Canada). This sample was incubated at 37°C for 3 hours at 200 rpm. 
Following incubation the sample was centrifuged at 4500 x g for 15 minutes at room 
temperature. The supernatant was discarded. The pellet containing the MAA was washed three 
times with 1X PBS, the PBS was removed and the pellet was stored at -20°C.  
  
Staphylococcus aureus V8 digestion of MAA 
The pellet containing the MAA (500 to 900 mg) was re-suspended with 10 mL of 8M urea 
(EMD Millipore, Etobicoke, Ontario, Canada), 1.5mL of 1M potassium phosphate buffer, 4 mL 
of 500 unit Endoproteinase Glu-C from Staphylococcus aureus V8 (Sigma Aldrich, Oakville, 
Ontario, Canada) and 4.5 mL of double distilled water (Milli-Q Advantage A10 System, EMD 
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Millipore, Etobicoke, Ontario, Canada) to yield final concentrations of 4M urea, 75mM 
potassium phosphate buffer and 100 units of Endoproteinase Glu-C from Staphylococcus aureus 
V8. The sample was incubated at 37° at 200 rpm for 30 minutes. Following incubation, the tubes 
were placed in a beaker of boiling water for two minutes to inactivate the V8 protease. The 
sample was centrifuged at 4,500 x g for 20 minutes at 4°C. The supernatant containing the 
soluble MAA was collected and dialyzed against double distilled water (Milli-Q, EMD 
Millipore, Etobicoke, Ontario, Canada) using 3.5K MWCO Dialysis Membrane (Thermo Fisher 
Scientific, Waltham, Massachusetts, USA) for 48 hours with water changes every 2 hours for the 
first 10 hours and every 4 hours for the remainder of time. The sample was transferred to a 50 
mL conical tube (Fisher Scientific, Mississauga, Ontario, Canada) and frozen at -80°C. Once 
frozen solid, the sample was lyophilized (FreeZone Plus 6 Liter Cascade Console Freeze Dryer, 
Labconco, Kansas City, Missouri, USA) for approximately 48 hours or until lyophilized 
completely. The lyophilized MAA was stored at -20°C until ready for use. Prior to use, the 
lyophilized MAA was dissolved in 1 mL of 1X PBS, pH 7.2 and protein concentration was 
determined using Bio-Rad DC Protein Assay (Bio-Rad Laboratories, Hercules, California, USA) 
  
Streptokinase C digestion of MAA 
The pellet containing the MAA (500 to 900 mg) was re-suspended with 10 mL of 8M urea 
(EMD Millipore, Etobicoke, Ontario, Canada), 1.5mL of 1M potassium phosphate buffer, 0.2 
mL of 10,000 unit Streptokinase C (Sigma Aldrich, Oakville, Ontario, Canada) and 8.3 mL of 
double distilled water (Milli-Q EMD Millipore, Etobicoke, Ontario, Canada) to yield final 
concentrations of 4M urea, 75mM potassium phosphate buffer and 100 units of Streptokinase C 
enzyme. The digestion reaction was done in the same manner as the Staphylococcal aureus V8 
protease digestions described above.  
Matrix Metalloproteinase-1 digestion of MAA 
Prior to use, the MMP-1 enzyme (EMD Millipore, Etobicoke, Ontario, Canada) was activated 
with trypsin (Trypsin from Bovine Pancreas, EMD Millipore, Etobicoke, Ontario, Canada) at a 
ratio of 10:1 MMP-1 to trypsin for 10 minutes at 25°C. The trypsin was inactivated with a 10-
fold excess of soybean trypsin inhibitor (EMD Millipore, Etobicoke, Ontario, Canada). The 
pellet containing the MAA (500 to 900 mg) was re-suspended with 10 mL of 8M urea (EMD 
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Millipore, Etobicoke, Ontario, Canada), 1.5mL of 1M potassium phosphate buffer, 0.225 mL of 
50 µg/mL MMP-1 (EMD Millipore, Etobicoke, Ontario, Canada) and 7.9 mL of double distilled 
water (Milli-Q EMD Millipore, Etobicoke, Ontario, Canada) to yield final concentrations of 4M 
urea, 75mM potassium phosphate buffer and 2 µg/mL of MMP-1. The sample was incubated at 
25°C at 200 rpm for 30 minutes. Following incubation, the reaction was stopped with 50 mM 
EDTA. The sample was centrifuged at 4,500 x g for 20 minutes at 4°C. The dialysis and 
lyophilization of the sample was completed as described above. 
4.3.4 Control Animals 
A negative control group consisting of 4 naive rats were intermixed amongst treatment groups 
and euthanized alongside treatment rats between day 26 and 42 of the experiment. 
4.3.5 Experimental Inoculations 
Prior to all inoculations rats were anesthetized using isoflurane gas (Halocarbon Products 
Corporation, River Edge, NJ, USA) provided through a flow by mask. The injection site was 
cleaned with an alcohol wipe and injections were completed as described below. 
Three groups of twelve 36 day old females were inoculated with either Staphylococcal V8 
protease digested MAA, streptokinase C digested MAA or matrix-metalloproteinase-digested 
MAA. Inoculations contained 400 µg solubilized MAA and an equal volume of incomplete 
Freund’s adjuvant and were administered intradermally at the base of the tail divided over two 
sites. The inoculations were administered on the first day and repeated on days 7 and 14. Ocular 
examinations were initiated on day 14 and repeated three times per week until euthanasia. Rats 
were euthanized between day 26 and 42.  
 
4.3.6 Euthanasia and Tissue Collection 
All rats received a lethal intraperitoneal injection of pentobarbital sodium (80 mg/kg; 54 mg/mL; 
Euthanyl Forte, Bimeda-MTC, Cambridge, Ontario, Canada). Once the palpebral reflex was 
absent, transconjunctival enucleations were completed and globes were immediately submerged 
in periodate-lysine-paraformaldehyde (PLP) fixative25. Following 24 hours of fixation, globes 
were dehydrated in sequential 70% ethanol (45 minutes), 90% ethanol (45 minutes), and 100% 
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ethanol (twice for 30 minutes each).  This was followed by immersion in Histo-clear (National 
Diagnostics, USA) twice for 30 minutes each immersion. Eyes were embedded under vacuum at 
54°C for 30 minutes then routinely processed in conventional paraffin25. Paraffin blocks were 
sectioned into 6 µm sections which were floated on a water bath at 40°C prior to transfer onto 
glass slides. Slides were dried, hematoxylin and eosin stained, and examined with light 
microscopy by a masked Diplomate ACVO. 
Sections from naive rats (n=4), V8MAA (n=12), SKMAA (n=12), and MMP-1 MAA 
(n=12) treated rats were evaluated using mouse anti-rat CD43 (clone W3/13) and CD45RC 
(clone OX-33) primary antibodies and secondary anti-mouse antibody.  Rat lymph node served 
as positive control tissue.   
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4.4 Results 
4.4.1 V8 Digested MAA 
 Three of 12 juvenile female rats inoculated with V8 protease digested MAA developed uveitis 
detected clinically (Figure 1.) and confirmed with light microscopic examination of 
immunohistochemically labelled slides in 2/3 affected rats (Figure 2.). The uveitis was detected 
ophthalmoscopically in two rats on day 17, was initially graded as 4/4 and persisted until 
euthanasia. The third rat developed unilateral uveitis on the 30th day, which resolved by the 33rd 
day and could not be detected with histologic examination of either eye after euthanasia.  Uveitis 
was confirmed in the two rats affected until euthanasia with CD43 and CD45RC positive 
labelled cells in their iris and ciliary body (Figure. 1). The remaining nine rats in this treatment 
group, which were normal clinically, did not have light microscopic or immunohistochemical 
evidence of uveitis. 
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Figure 4- 1.  Clinical images of a rat inoculated with V8MAA demonstrating severe uveitis in 
the right (A) and left (B) eyes. The eye in A demonstrates dyscoria and iridial hyperemia. The 
eye in image B demonstrates miosis, iridial hyperemia and obstruction of the pupil with aqueous 
flare and fibrin. C represents a control eye. 
  
A B
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Figure 4- 2. Uveitis in a V8 protease MAA inoculated rat labelled with CD43 (A) and CD45RC 
(B) immunohistochemistry. The uveitis was graded 1/4 the day prior to euthanasia. A brown 
labelling dye highlights CD43 (A) positive cells and CD45RC (B) cells. Slight background 
staining of the ciliary epithelium and posterior iris epithelium is observed. (80X) 
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4.4.2 Streptokinase C Digested MAA 
 Two of 12 juvenile female rats inoculated with streptokinase C soluble MAA developed uveitis 
which was evident on biomicroscopic examination (Figure 3.). One rat was affected bilaterally 
on day 22 and clinical resolution occurred by day 34. This rat was euthanized on day 36 and did 
not have detectable CD45RC and CD43 cells within the iris and ciliary body.  The second rat 
developed uveitis unilaterally on day 33 post inoculation, was graded 1/4 and resolution occurred 
by day 35. This rat was also negative for both CD45RC and CD43 cells within the iris and ciliary 
body. A third rat did not develop uveitis that could be detected clinically, however, 
immunohistochemical examination revealed CD45RC and CD43 cells present in the ciliary body 
(Figure 4). 
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Figure 4- 3. Clinical photos of a SK MAA inoculated rat demonstrating grade 1/4 uveitis OD 
with dyscoria and mild iris hyperemia (A), and grade 2/4 uveitis OS demonstrating miosis and 
mild iris hyperemia (B). Image C is an unaffected control eye. 
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Figure 4- 4. Cyclitis in a streptokinase C MAA inoculated rat labelled with CD43 (A) and 
CD45RC (B) immunohistochemistry. The brown stain highlight CD43 (A) and CD45RC (B) 
cells. Cyclitis and iritis had not been detected with biomicroscopic examination. 40X 
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4.4.3 Matrix Metalloproteinase-1 Digested MAA 
There was no clinical evidence of uveitis in any of the rats inoculated with the MMP-1 digested 
MAA. Similarly, none of the MMP-1 MAA treated rats had CD43 or CD45RC labelled cells in 
their iris and ciliary body. 
 
4.4.4  Control Groups: 
 Uveitis was not detected in control rats by either clinical or with immunohistochemical 
examinations with CD43 and CD45RC labelling.  
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4.5 Discussion 
Complete Freund’s adjuvant contains inactive mycobacteria known to stimulate cell-mediated 
immunity, tumor necrosis factor dysregulation, and uveitis16-19. Incomplete Freund’s adjuvant 
provides a water-oil emulsion to facilitate inoculation administration without immune 
stimulation. This study demonstrated that three inoculations of either streptokinase C or V8 
protease digested MAA induced uveitis when administered with incomplete Freund’s adjuvant. 
This is contrary to previous reports in which soluble MAA was not pathogenic as a sole agent 
and required use of complete Freund's adjuvant or inoculation in its intact form where the MAA 
backbone was speculated to act as an adjuvant8,10. Complete Freund's adjuvant alone causes 
uveitis and arthritis16-17 confounding results when it is used in conjunction with soluble MAA. 
The added use of complete Freund’s adjuvant adds additional variables including emulsion 
stability and adjuvant ratio to inoculum. There were three main differences in experimental 
design between this study and earlier reports which did not find digested MAA antigenic. First, 
we increased the dose of Staphylococcal aureus V8 protease digested MAA from 100 µg to 400 
µg, the injection site was changed to the tail base from the footpad, and lastly, inoculations were 
repeated every seven days for three treatments. It is not known if one or all of the changes in 
design accounted for the difference in pathogenicity.  Matta et al demonstrated IV administration 
of MAA in previously sensitized rats conferred dose dependent protection, with rats receiving 
higher doses demonstrating complete tolerance14.   
 
Streptokinase C digestion of MAA was evaluated for the first time and proved to induce uveitis 
in our study.   Further studies would be required to verify this observation and ascertain the role 
of streptokinase C in uveitis etiopathogenesis. It is possible that streptokinase C digests uveal 
collagen in the same or similar location exposing the 22 KDa fragment of type I collagen that is 
known to induce uveitis. 
 
Data from this study supports a possible role of Streptococcus and associated streptokinase C and 
Staphylococcus and associated V8 protease as a triggers for autoimmune uveitis. It is plausible 
that an infection with either agent could result in breakdown of endogenous collagen and 
exposure of endogenous MAA.  Intravenous streptokinase C has been associated with the 
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development of uveitis in humans20, while Streptococcus has demonstrated a role in uveitis and 
arthritis in both humans and rats21-22. 
 
 To the authors’ knowledge this was the first study to evaluate for the potential pathogenicity of 
MMP-1 digested MAA.  Uveitis was not observed clinically nor with CD45RC and CD43 
immunohistochemistry. MMP-1 cleaves MAA into a fragment that is between 20 and 25 KDa 
which is similar to the 22 kDa fragment of type 1 alpha II chain of MAA known to be 
antigenic12. It is been speculated that MMP-1 could play a role in exposure of MAA in vivo 
leading to the development of uveitis12. The results of our investigation did not support this 
theory and more studies are required to determine if MMP-1 plays a role in antigen exposure in 
autoimmune uveitis. 
 
Conclusions 
Streptokinase and V8 protease solubilized MAA induce uveitis without the use of Complete 
Freund’s Adjuvant, while MMP-1 solubilized MAA did not. 
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5. Conclusions 
Examining the influence of sex on EAAU onset we found juvenile female rats had the earliest 
onset of disease. Although these results were not significantly different the trend mirrors 
observations in JIA uveitis where females have an earlier onset of uveitis. Girls with JIA 
developing uveitis are on average 2.9 years old, where boys are 8.1 years old1. The onset of 
uveitis we observed between the age/sex groups in rats ranged from 16.25 days to 20.00 days 
which was similar to other reports in juvenile male rats2-6.Statistical significance was not 
achieved for the differences in onset between sex and age groups, as these experiments lacked 
the necessary power to determine statistical differences of modest magnitude.  
In comparing the biomicroscopic manifestations of uveitis between age and sex groups we found 
that severity at peak disease did not differ between age or sex groups. All but one adult male rat 
developed a severe bilateral uveitis manifesting with marked miosis, fibrin in the anterior 
chamber, iridial hyperemia and conjunctival injection. The adult male only developed a 
unilateral mild uveitis at the end of the study. With only four rats per age/sex group, the 
significance of the variability in this single rat’s disease could reflect a true difference in disease 
manifestation in this age and sex group or it could just be an outlier that coincidentally reflects 
that age of onset pattern between males and females with JIA uveitis.  Future work including 
larger group sizes to allow enough statistical power to confirm or deny the trends observed in our 
work are needed. 
Changes in vitreous cytokines were observed, both between treated rats with uveitis and controls, 
and between different age and sex groups. Due to the discovery nature of this study, we had a 
limited number of rats in each age/sex group, and a high number of comparisons (27 cytokines) 
this made statistical significance unlikely. The results provide descriptive information and will 
allow us to narrow our target group of inflammatory cytokines for future work. Cytokines with 
differences that should be evaluated further included MIP2, RANTES, IL-1a. IP-10, GROKC, 
IL-18, MCP1, IL-10, TNFα, and IL-13. These were the cytokines with the 10 lowest p values. In 
aqueous humor of children with JIA-uveitis IL -2, IL -6, IL -13, IL -18, IFN-γ, TNF-α, sICAM-
1, RANTES and IP-10  have been reported to be elevated7. All of these except IL-13 and 
cICAM-1 were evaluated in our study which found no significance between rats with uveitis and 
controls. Another study on children with JIA-uveitis evaluating aqueous in children with inactive 
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disease found IL-8, TGFβ-1, TGFβ-2, TGFβ-3, serum amyloid A, and TNF-α levels to be 
increased in JIA-uveitis affected children8. While the inactive disease profile is likely more 
reflective of the stage of uveitis in the rats at the time of vitreous collection we did not evaluate 
IL-8, TGFβ-1, TGFβ-2, TGFβ-3, or serum amyloid A and we did not see a difference in TNF-α 
levels. Future work evaluating cytokines in rats with uveitis should include IL-8, TGFβ-1, 
TGFβ-2, TGFβ-3, and serum amyloid A to determine if a similar profile is seen. 
Harvest of vitreous instead of aqueous was done in our study as our collection point was later in 
the disease. Aqueous humor turnover is more rapid and therefore was less likely to show 
cytokine changes. 
Inhibition of specific cytokines in the course of JIA is credited for the improvement in outcomes 
observed in affected children over the recent decades. These medications include TNFα 
inhibitors and monoclonal antibodies targeting IL-2 or IL-6 receptors9. We did not observe a 
difference between IMMA rats with uveitis and controls in the levels of IL-2, IL-6, or TNFα. 
This may be reflective of our late harvest of vitreous or be due to differences in species or 
disease processes. 
Previous studies evaluating cytokines in EAAU harvested rats sequentially throughout the 
disease process, and most cytokine elevations typically occurred between day 9 and 18 post 
inoculation10-12. In contrast, we harvested our rats at a single time-point on days 27-29. The later 
harvest was intended to allow adequate time for development and evaluation of joint pathology. 
Future work should include a sequential harvesting schedule evaluating for age/sex differences in 
the cytokine cascade throughout the course of disease. 
 Inoculation of rats intradermally at the base of the tail was found to produce equivalent uveitis 
to rats inoculated using the traditional technique in the foot pad. Either injection location is 
straight forward and easy to perform. In studies requiring evaluation of joints, the tail base 
injection site should be used. 
During the harvest of eyes, rats were also exsanguinated. We plan to evaluate their serum 
cytokine profiles. It will be valuable to determine if the aqueous cytokine profiles mirror those of 
the serum and if there are systemic differences between age and sex groups. Future work with 
this group of rats includes evaluation of their joints. Unpublished work by members of our group 
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identified arthritis on micro computer tomography in rats inoculated with soluble MAA and 
complete Freund’s adjuvant.  While on physical examination the rats in the current experiment 
did not appear to have any evidence of arthritis, we plan to complete micro computer 
tomography and these results will be part of a later study.  
For the first time we demonstrated that three inoculations of either streptokinase C or V8 
protease digested MAA induced uveitis with incomplete Freund’s adjuvant rather than complete 
Freud’s adjuvant. Complete Freund’s adjuvant, contains inactive mycobacteria known to 
stimulate cell-mediated immunity, tumor necrosis factor dysregulation, and uveitis13-16. 
Incomplete Freund’s adjuvant provides a water-oil emulsion to facilitate inoculation 
administration without immunostimulation. Previous reports have found soluble MAA has not 
been capable of inducing uveitis without complete Freund's adjuvant17-18. We do not know if our 
increased dose, tail base injection site, or repeated of inoculations all accounted for the difference 
in pathogenicity of if only one factor contributed.  We plan to image the joints of these rats using 
micro computer tomography to evaluate for arthritic change. In a pilot study members of our 
group identified arthritic changes in rats inoculated with soluble MAA and complete Freud’s 
adjuvant. Comparison of these rats induced without the use of complete Freund’s adjuvant will 
allow us to understand the separate roles of soluble MAA and complete Freund’s adjuvant in the 
arthritis we had observed. It should also be considered that the soluble MAA could have been 
incompletely digested or contaminated with IMAA.  
Streptokinase C digestion of MAA was evaluated for the first time and proven to induce uveitis 
in our study.   This corroborates a possible role of Streptococcus and associated streptokinase C, 
and Staphylococcus and associated V8 protease as a triggers for autoimmune uveitis. It is 
plausible that an infection with either agent could result in breakdown of endogenous collagen 
and exposure of endogenous MAA.  Intravenous streptokinase C has been associated with the 
development of uveitis in humans19, while Streptococcus has demonstrated a role in uveitis and 
arthritis in both humans and rats20-21. We do not know the mechanism of pathogenicity of the 
streptokinase C digested uveitis, it is possible that streptokinase C digests uveal collagen in the 
same or similar location to V8 protease exposing the known 22 KDa fragment of ocular type I 
collagen that is antigenic.   
92 
 
Uveitis was not observed in rats inoculated with MMP-1 digested MAA. MMP-1 cleaves MAA 
into a fragment that is between 20 and 25 KDa which is similar to the 22 kDa fragment of type 1 
alpha II chain of MAA known to be antigenic5. The lack of antigenicity of MMP-1 digested 
MAA did not support the theory that MMP-1 could play a role in exposure of MAA in vivo. As 
elevated serum and synovial fluid levels of MMP‐3 are found in patients with active 
polyarticular and oligoarticular JIA22-23 and increased concentrations of MMP-2, MMP-3, and 
MMP-9 were observed in the aqueous of children with inactive JIA-uveitis8 future work should 
include evaluation of these proteases. 
A common collagen trigger for autoimmune arthritis and uveitis in the Lewis rat was not found 
in our experiment. Neither commercial type I nor II collagen in their intact form or digested form 
resulted in uveitis.   As expected, intact type II collagen inoculation resulted in arthritis in 28/44 
rats, however, none of these rats developed uveitis. This was in contrast to previous work by 
Petty et al14 in which clinical uveitis was reported in 4/40 female Sprague-Dawley rats 
inoculated. The difference may be related to differences in genetic susceptibility between Lewis 
and Sprague-Dawley rats, or differences in experimental design.  Inclusion of Sprague-Dawley 
rats in treatment groups would be useful in confirming the previous findings by Petty et al14 and 
evaluating the pathogenesis of shared inflammatory response between the joint and eye.  
Rats treated with type II collagen digested in either V8 protease or MMP-1 did not develop 
arthritis.  The reason for the loss of antigenicity with collagen digestion is unknown, however it 
is likely the antigenic epitope became damaged in the digestion process. These results make a 
direct role of V8 protease or MMP-1 in the exposure of a pathogenic antigen in vivo less likely as 
they in-fact diminished the arthritic antigenicity of type II collagen, the opposite effect to what 
was hypothesized. This reduced antigenicity somewhat parallels the results with MAA, where 
intact MAA induces uveitis in 100% of rats inoculated while the digested forms in our study had 
reduced disease incidence. We speculate that the digestion process may damage the antigenic 
epitope. Determining the epitope targeted in both MAA and type II collagen induced disease 
would advance our understanding of the trigger initiating uveitis or arthritis in the rat, which may 
have translational value to humans. Work in experimental autoimmune uveitis in rats has 
demonstrated molecular mimicry between retinal S-antigen peptide PDSAg and class I HLA 
B27PD amino acids 125-13824-28. 
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 Despite use of over 200 animals in this project a major limitation of this work was our small 
group sizes. The discovery nature of the work resulted in many groups of animals inoculated and 
failing to developing disease. This was predominantly the case with type I collagen derived from 
bovine skin, as it was not pathogenic intact or digested. The negative results speak to the 
decreased likelihood that type I collagen derived from bovine skin,  plays a role in either the 
development of uveitis or arthritis.  
Use of an animal model has inherent limitations as rats are not humans and experimental disease 
is not equivalent to naturally occurring morbidities. Determining where the differences occur 
between animal models and naturally occurring human disease plays a valuable role in 
developing our understanding of the disease and evaluating targets for treatment. Use of animal 
models allows for more extensive evaluation of pathology as more invasive tissue harvest is 
possible. 
In conclusion, our animal model work does not suggest a role of type I collagen derived from 
bovine skin, in uveitis or arthritis. Consistent with previous studies we were able to induce 
EAAU with intact MAA, a uveal form of type I collagen. Differences in uveitis manifestations 
were observed between age and sex groups that should be further evaluated using experimental 
designs with adequate power to determine their significance. Streptokinase C was identified as a 
new agent capable of exposing the antigenic sequence of soluble MAA and continued work in 
this area is needed to determine its role in JIA-uveitis. Uveitis was induced without the use of 
complete Freund’s adjuvant and we await micro computer tomography results of the joints to 
determine if MAA could be a common trigger of arthritis and uveitis.  
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